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ABSTRACT 
 
  The purpose of these studies was to investigate the implications of 
variability in virulence, genetics and antigenic profiles among field isolates of 
Mycoplasma hyopneumoniae. Increased virulence was compared with in vitro and 
in vivo growth characteristics of the organism and with immune parameters in the 
pig, although none was found to be significantly correlated. The impact of 
proteomic and genetic variation among field isolates on diagnostic assays was 
examined by both in vivo and in vitro studies. Three enzyme-linked 
immunosorbent assays (ELISAs) used in the United States were compared and 
shown to not detect all isolates of M. hyopneumoniae equally. Similarly, 
polymerase chain reaction (PCR) assays were tested against a panel of M. 
hyopneumoniae field isolates and it was shown that some isolates are not detected 
by all published PCR assays. Therefore, two new real-time PCR assays were 
developed that appear to be both sensitive and specific for M. hyopneumoniae. 
The ability of a commercial vaccine to protect against field isolates of M. 
hyopneumoniae was evaluated in a challenge study using two recent field isolates. 
One isolate produced nearly twice as many macroscopic lung lesions as the other 
isolate, but vaccinated pigs had less pneumonia compared to non-vaccinated pigs 
in both challenge groups. Together these results demonstrate that differences exist 
among isolates of M. hyopneumoniae in the field at the genetic and antigenic level 
and that these differences impact the virulence of the organism, diagnostic 
capabilities in the pig, and the prevention of M. hyopneumoniae-associated 
disease. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
Introduction 
Mycoplasma hyopneumoniae, the causative agent of enzootic pneumonia of pigs, is 
among the most significant pathogens of swine today leading to economic losses for 
producers world-wide. Mycoplasma hyopneumoniae is also a key component of the 
porcine respiratory disease complex which further increases the impact of this organism 
in pigs through enhanced pneumonia by potentiating and prolonging the disease caused 
by other organisms such as porcine reproductive and respiratory syndrome virus 
(PRRSV) and porcine circovirus type 2 (PCV2). Although M. hyopneumoniae was first 
described in 1965, relatively little is known about this organism due to its fastidious 
growth characteristics and unique genetic features that impede the use of routine genetic 
manipulations commonly employed to assign gene functions. In addition, while 
differences in protein expression and gene expression among isolates of M. 
hyopneumoniae have been identified, little is understood concerning the implications for 
virulence, therapeutics and diagnostics that this variation may have. The studies 
performed here investigated the impact that different field isolates of M. hyopneumoniae 
had on these factors. 
Dissertation Organization 
This dissertation is organized into six chapters. Chapter one is the introduction to M. 
hyopneumoniae. The next four chapters describe research performed that have been or 
will be submitted for publication. Chapter two investigated the differences in virulence 
between field isolates of M. hyopneumoniae. Chapters three and four describe the impact 
that genetic and protein-expression differences among field isolates of M. 
hyopneumoniae have on the ability of commonly used diagnostic procedures to detect the 
organism. Chapter five measures the ability of a commercial vaccine to protect against 
two virulent field isolates of M. hyopneumoniae. A general conclusion and future studies 
comprise Chapter six. The presentation of chapters two through five follow the style of 
the journal to which they are being or were submitted. 
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Literature Review 
Mollicutes 
The class Mollicutes includes eight genera and over 200 members (http://www.the-
icsp.org/subcoms/mollicutes.htm). Organisms in this class are pleomorphic due to the 
lack of a cell wall (Mollicutes means ‘soft skin’) and the presence of an internal 
cytoskeleton in some species (70, 71). Mollicutes are the smallest self-replicating 
organisms known and have genomes ranging from 577-2220 kilobase pairs (69). They 
are filterable organisms with diameters ranging from 0.3-1 µm (69). It is thought that 
they attained their small genomes through degenerative evolution from a gram-positive 
ancestor (43). During this process they lost a number of important metabolic pathways 
including those for phospholipid, amino acid, and purine and pyrimidine synthesis. The 
Mollicutes are also unique in that their genomes contain a high A+T content from 60-77 
mol% (32) and they utilize UGA codons to encode tryptophan rather than a stop codon 
(58, 104). While capable of translating all available codons, they possess a greatly 
reduced number of tRNAs (around 20 of the 62 potential tRNAs) (58). This combination 
of traits makes members of the class Mollicutes highly dependent on their host for growth 
and survival, and also highly susceptible to environmental conditions. 
Mollicutes are pathogens and commensals of a diverse variety of hosts including both 
animals and plants (and their insect vectors). Many of the mammalian Mollicutes reside 
on mucosal surfaces of the respiratory or urogenital tract of their hosts, or in joint spaces 
(83). Most of these organisms are extra-cellular, but evidence exists for some Mollicutes 
residing intracellularly (7, 77). A few members are blood-borne (50). Most clinical 
isolations of species in the class Mollicutes belong to the genus Mycoplasma (34). Many 
of the Mycoplasmas are slow-growing and nutritionally demanding in culture, requiring 
enriched media. Therefore, the true significance of most Mycoplasmas is currently under 
appreciated because of low rates of isolation and the lack of reliable detection methods 
for these organisms (34).  
In addition, surveys of tissue cell cultures have found that from 15-80% are 
contaminated with Mollicutes (98). As many as 20 different Mollicute species have been 
found in tissue culture systems with Mycoplasma arginini, Mycoplasma fermentans, 
Mycoplasma hyorhinis, Mycoplasma orale and Acholeplasma laidlawii accounting for 
95% of these occurrances (63, 95).  
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Mycoplasmas and Acholeplasmas of swine 
While M. hyopneumoniae is the most notable mycoplasma infecting swine, a number 
of other members of the class Mollicutes have also been identified in pigs. In the 
respiratory tract, Mycoplasma  hyorhinis and Mycoplasma flocculare are commonly 
isolated with Mycoplasma hyosynoviae being isolated occasionally. None of these 
mycoplasmas (aside from M. hyopneumoniae) are considered pathogens when found in 
the respiratory tract, although M. hyorhinis and M. hyosynoviae are capable of inducing 
arthritis (67, 68). Mycoplasma suis is a blood-borne organism that until recently was 
classified as Eperythrozoon suis (59, 60). It adheres to the surface of erythrocyte 
membranes and induces anemia (84). Acholeplasma laidlawii and Acholeplasma 
granularum have both been isolated from clinical samples from pigs, but their 
contribution to disease is unknown at this time (26). 
Mycoplasma hyopneumoniae has a genome size of 892 kilobase pairs and one of the 
highest A+T contents among the Mycoplasmas (71%) (55). Mycoplasma hyopneumoniae 
is one of the most fastidious mycoplasmas to culture. It requires a highly-enriched media 
and is easily overgrown by other species of mycoplasmas and other types of bacteria that 
also inhabit the respiratory tract (24). In addition, it does not grow readily on agar making 
traditional titering methods impossible. Therefore, a less-precise method based on color-
changing units (CCU) is usually employed (91). Mycoplasma hyopneumoniae’s growth 
characteristics also make performing minimum inhibitory concentration (MIC) assays 
testing for antibiotic sensitivity tedious and cumbersome (28). New methods using flow 
cytometry have been described to detect mycoplasmas, including M. hyopneumoniae, 
which may greatly enhance our ability to quantify these organisms (5). Three strains of 
M. hyopneumoniae: 232, J and 7448 have been completely sequenced (55, 99). While 
sequencing of M. hyopneumoniae has provided important information about its genome, 
over half (56%) of the gene sequences identified are unique to M. hyopneumoniae (55). 
Currently gene deletion experiments commonly used to assign functions to genes in other 
organisms cannot be performed because of M. hyopneumoniae’s unique genetics and 
poor growth characteristics on agar. As a result, our knowledge of the function of most of 
M. hyopneumoniae’s genes is lacking. 
Mycoplasma hyopneumoniae 
Disease characteristics 
Mycoplasma hyopneumoniae is the causative agent of enzootic pneumonia and is 
found in most pig-producing countries worldwide. It induces a chronic pneumonia with 
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high morbidity and low mortality with the most notable clinical sign being a dry, non-
productive cough (73, 85, 101). Mycoplasma hyopneumoniae colonizes the ciliated 
epithelium of the pig respiratory tract (10, 78, 107), but in specific pathogen-free pigs has 
been demonstrated to spread systemically (possibly through the blood and/or lymphatics) 
in the early phase of infection (44). After M. hyopneumoniae attaches to the ciliated 
respiratory epithelium it induces clumping of the cilia through an unknown mechanism 
(18) leading to impairment of the mucociliary apparatus. This is thought to predispose the 
pig to secondary infections. Macroscopic lesions appear primarily cranial-ventrally as 
well-demarcated, tan-to-purple areas of lung consolidation. Microscopically M. 
hyopneumoniae infection is characterized by peribronchiolar, peribronchial, and 
perivascular areas of lymphoid hyperplasia with mononuclear infiltrates into the affected 
airways. Both the macroscopic and microscopic lesions are characteristic, but not 
pathognomonic of M. hyopneumoniae infection. Factors affecting the severity of disease 
include, but are not limited to environmental conditions (cleanliness of the environment 
including air quality), presence of other pathogens, stocking density, production system 
(continuous flow versus all-in/all-out), and vaccination status (42, 81, 101). Mycoplasma 
hyopneumoniae-induced pneumonia takes months to resolve and pigs can carry the 
organism long-term (12, 85). 
Although M. hyopneumoniae is a primary pathogen, it is more significant as a 
member of the porcine respiratory disease complex (PRDC). This complex consists of 
viruses including PRRSV, PCV2, swine influenza virus (SIV) and bacteria such as 
Pasturella multocida, Bordetella bronchiseptica, Streptococcus suis, along with M. 
hyopneumoniae. Of the pathogens associated with the PRDC, M. hyopneumoniae is 
recognized as one of the most commonly isolated and most clinically important. 
Mycoplasma hyopneumoniae contributes not only additively to the disease complex, but 
has been demonstrated to potentiate and prolong the disease caused by both PRRSV and 
PCV2 (62, 96). The PRDC is the most significant source of economic loss in the swine 
industry today, but little is known about the mechanisms of pathogenesis or interactions 
between the organisms involved.  
Epidemiology 
The most important mode of transmission of M. hyopneumoniae to a naïve herd is 
through introduction of a subclinically infected carrier pig to the system (53, 65). There is 
a relatively high risk of this occurring because M. hyopneumoniae often spreads slowly 
within a herd leading to a gradual onset of disease in the population. Airborne 
transmission has been demonstrated, but is considered a less important source of 
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infection as M. hyopneumoniae is relatively labile in the environment. Transmission by 
this route is more likely to occur in humid, windy conditions (27). Dry, freezing, and 
rainy weather are negatively associated with spread of M. hyopneumoniae (88).  
Within a herd, spread occurs through both vertical and horizontal means. Piglets can 
be infected from their sows, who may actively shed the organism at the time of 
parturition and lactation (12, 23, 82). Maternal antibodies provide some protection from 
severity of disease, but do not prevent colonization from occurring in the piglets (45, 
103). Pigs that are infected prior to weaning go on to spread it to other pigs when litters 
are mixed at the grow-finish stage (101). 
Field isolate diversity 
Much research highlighting differences between field isolates of M. hyopneumoniae 
exists. Studies using SDS-PAGE alone, or in combination with western blot 
immunoassays have been used extensively. Considerable variation in banding patterns 
among a number of isolates has been demonstrated using total protein and glycosylated 
protein-only staining techniques, or reacting with convalescent sera or monoclonal 
antibodies (6, 39, 79). Each of these assays identified differences in expression of several 
proteins among the isolates tested. Antigenic diversity has also been demonstrated using 
antisera raised against field isolates of M. hyopneumoniae in growth inhibition, metabolic 
inhibition and 2-dimensional immunoelectrophoresis assays (72).  
Comparison of the three genomes of M. hyopneumoniae that have been sequenced 
provides evidence of intra-specific rearrangements in each of these strains (99). Unlike 
other mycoplasma species, M. hyopneumoniae has relatively few tandem repeats within 
gene coding sequences that impact size or expression of surface proteins (55). However, 
amplification of DNA sequences containing variable numbers of tandem repeats (VNTR) 
has been used to differentiate between field isolates (17). Another study evaluating 
molecular techniques including amplified fragment length polymorphism analysis, 
random amplified polymorphic DNA (RAPD) analysis, restriction fragment length 
polymorphism analysis and VNTR analysis were able to distinguish between isolates of 
M. hyopneumoniae from an international collection (87). Multilocus sequence typing has 
also been used for typing field isolates of M. hyopneumoniae (48). 
Although a considerable amount of research has been conducted to show differences 
between field isolates of M. hyopneumoniae, especially at the levels of protein and gene 
expression, few studies have been able to correlate any of these changes with differences 
in virulence. Vicca, et al. found a link between a 5000 bp fragment and increased 
virulence in a small number of isolates using RAPD analysis (102). Another study 
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investigating two isolates from the Vicca, et al. study demonstrated that a high-virulent 
isolate had quicker generation times in vitro than did a low-virulent isolate suggesting a 
correlation of virulence to this trait (52). 
Virulence factors 
In the respiratory tract M. hyopneumoniae attaches to the ciliated respiratory 
epithelium. This association has been shown to be required for virulence, and that the 
protein P97 is involved in this process (29). P97 is part of an operon with two open-
reading frames, P97 and P102 (31). The P97 structural gene has two repeat regions, R1 
and R2, and monoclonal antibodies that block attachment of M. hyopneumoniae to the 
cilia in vitro (105) have been shown to bind to the R1 region (30, 54). Minion et al. also 
showed that eight or more repeats within the R1 region was sufficient for cilium binding 
(54). Additional potential adhesins have been identified (11, 15) (GenBank AF279908), 
but their role in binding has not been confirmed. 
Attachment of M. hyopneumoniae to the respiratory epithelium leads to clumping of 
the cilia and ciliostasis in these cells and ultimately to loss of the cilia. This phenomenon 
has been demonstrated in vitro using tracheal ring cultures, but the mechanism through 
which this occurs remains to be elucidated (18). Intracellular free-calcium release by the 
epithelial cells has been correlated with this process (64), and a 54 kDa membrane 
protein shown to be cytopathic to human lung fibroblasts in culture may be involved (25). 
Mycoplasma hyopneumoniae is surrounded by a capsular matrix. Although no clear 
connection has been made, a thinner capsule is produced after serial passage in vitro, and 
this was correlated with decreased pathogenicity in vivo (93). It is unclear what other 
effects occurred through serial passage that also may have affected virulence.  
Because M. hyopneumoniae lacks the ability to synthesize many of its own building 
blocks for growth, the organism requires mechanisms for the acquisition of molecules 
such as cholesterol, phospholipids, purines, pyrimidines, and amino acids. The means by 
which M. hyopneumoniae extracts these macromolecular precursors from the host are 
largely undefined but are generally thought to involve some means of host-tissue 
destruction that contributes to pathogenesis. A 54 kDa protein may be involved directly 
in causing cell death, and/or the effect may be indirect, caused by the immune response 
of the pig to infection (25). Neutrophils are a prominent cell type in infected airways, and 
these cells are known to release superoxide radicals and other toxic substances that kill 
not only pathogens, but also host cells. 
In addition, lipoproteins have been isolated from several species of mycoplasma 
including M. fermentans, M. pneumoniae, and M. arthritidis that are inflammatory in 
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nature and may act as non-specific mitogens (21, 36, 37). While no specific lipoprotein 
from M. hyopneumoniae has been identified with these capabilities, there is data to 
suggest that at least one exists. One study found that lymphocytes are non-specifically 
stimulated by unidentified membrane constituents of M. hyopneumoniae (51). Over 50 
lipoproteins have been predicted through sequence analysis of the genome (55), and a 
microarray of M. hyopneumoniae genes demonstrated that transcription of three of these 
predicted lipoproteins are upregulated during heat-shock conditions (a measure of the 
stress response) in vitro (40). This non-specific stimulation may be the cause of the 
peribronchiolar, peribronchial and perivascular lymphoid hyperplasia, leading to an 
ineffective immune response and tissue damage that likely benefits the growth of M. 
hyopneumoniae.  
Immune response 
Immunopathologic changes are a major component of M. hyopneumoniae-induced 
disease, although little is understood about the mechanisms underlying this process. 
Interestingly, thymectimized pigs treated with anti-thymocyte serum displayed decreased 
lesion severity in response to experimental M. hyopneumoniae infection (94) suggesting 
the cell-mediated immune responses may actually contribute to the pathology observed 
during infection. This study also found that the thymectomized/anti-thymocyte treated 
pigs infected with M. hyopneumoniae had a greater tendency for systemic spread of M. 
hyopneumoniae compared to pigs that only received M. hyopneumoniae challenge. In 
addition, the thymectomized/anti-thymocyte treated pigs infected with M. 
hyopneumoniae had increased intra-luminal exudate compared to pigs that only received 
the M. hyopneumoniae challenge, and the cell types comprising the exudate were 
different between the two groups. In the thymectomized/anti-thymocyte treated pigs the 
predominant intra-luminal cells were large mononuclear cells, whereas in the group that 
only received M. hyopneumoniae, most of the cells were polymorphonuclear leukocytes. 
The importance of the systemic spread and differences in the cellular response is 
unknown. 
Mucosal epithelial cells have a critical role in transmitting signals between microbial 
pathogens and the underlying cells in the mucosa (33). While M. hyopneumoniae binds 
only to the extracellular matrix associated with the cilia (107), there is evidence that these 
epithelial cells respond to M. hyopneumoniae binding. When M. hyopneumoniae attaches 
to cilia, increases in the intracellular concentration of calcium are observed in the 
epithelium (64). This increase in calcium suggests the involvement of G-protein mediated 
cell signaling leading to upregulation of transcription factors and ultimately cell 
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activation. This activation likely influences the local milieu of cytokines and chemokines 
secreted at the site of infection, which are critical for determining the outcome of both the 
innate and adaptive immune responses.  
Toll-like receptors (TLR) may be an important link between the previously discussed 
lipoproteins in the membrane of M. hyopneumoniae and the inflammation observed 
during infection. Specifically, TLR2 and TLR6 have been shown to mediate TNFα 
expression after infection with M. hyopneumoniae (57). Toll-like receptors 2 and 6 are 
expressed by macrophages and mediate an inflammatory response by initiating an 
intracellular signaling cascade that culminates in the transcription of inflammatory 
cytokines. While TLR4 binds to lipopolysaccarides (LPS), TLR2 and TLR6 activate the 
same signaling cascade by binding lipoproteins. Interleukin (IL)12 and IL10 have been 
associated with Th1 and Th2 lymphocyte responses, respectively. Increased levels of 
both cytokines have been measured in the lungs of M. hyopneumoniae-infected pigs (74, 
97). To protect against M. hyopneumoniae, an extracellular pathogen, it is thought that a 
controlled Th1 response in the lungs would be the most effective immune response, but 
the cytokine profile after infection is mixed. Production of proinflammatory cytokines 
IL1, IL2, IL8, IL12, IL18 and TNFα suggest a Th1 response, but the presence of 
increased levels of IL4, IL6 and IL10 support a Th2 response (3, 4, 16, 56, 74, 75). This 
suggests the presence of a conflicting and ineffective immune response. 
The lack of immune-related reagents and an in-depth understanding of the pig 
immune system have hampered attempts to understand the pathogenesis of M. 
hyopneumoniae and other disease-causing agents in swine. In recent years a significant 
portion of the sus scrofa genome has been sequenced and annotated allowing for more 
detailed studies. Microarrays are a relatively new technology, which can be used to 
screen samples for up- or down-regulation of large numbers of genes simultaneously. An 
array of swine genes has been developed, but is based on muscle tissue so few immune-
related genes were included (106).  
Vaccines 
The commercial M. hyopneumoniae vaccines currently on the market are all killed 
whole-cell or membrane preparations with a variety of adjuvants. No modified-live 
vaccines exist. These bacterins have been shown to decrease mycoplasmal pneumonia but 
do not prevent colonization of the host, and not all preparation methods have been shown 
to be effective. Recently, increased numbers of vaccine failures have been reported. This 
may be due to genetic variability in M. hyopneumoniae field strains (41). One study 
comparing various vaccine preparations found that extracts prepared according to a 
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freeze-thaw procedure were variable in protective activity and, in some instances, 
enhanced lesion development (76). It is presently unknown what specific components of 
M. hyopneumoniae are important to include (or possibly exclude) in a vaccine in order to 
provide the maximum protection. Experimental studies using sub-unit or DNA vaccines 
have shown some protection against pneumonia, but none were more effective than 
whole-cell bacterins (22, 35, 80). One explanation for this is that single-antigen vaccines 
are less-capable of providing protection against complex bacterial pathogens.  
Currently available commercial vaccines increase the local and systemic levels of 
antibodies. However, there is pig-to-pig variation in the magnitude of the immune 
response observed in each pig that does not correlate well with protection. As with 
factors surrounding lesion formation, the protective mechanism by which these vaccines 
act to decrease pneumonia has yet to be defined. To date, most challenge studies testing 
the efficacy of M. hyopneumoniae vaccines have relied on the use of a few, well-
characterized strains. The effect on vaccine efficacy of the recently reported differences 
in virulence among field isolates of M. hyopneumoniae has not been determined. 
Diagostics 
Culture 
Typically, isolation and culture of an organism is considered the “gold” standard for 
diagnosis and confirmation of its presence in the host. However, isolation of M. 
hyopneumoniae is impeded by a number of factors. This organism is nutritionally 
demanding and is cultured in a highly enriched growth media that requires M. 
hyopneumoniae antibody-negative serum (24). In addition, primary isolation commonly 
requires four to eight weeks to reach measurable levels in culture. Contamination from 
other bacteria and mycoplasmas that grow more readily in the media frequently preclude 
attempts to obtain pure cultures of the organism. Furthermore, once a mycoplasma 
culture is obtained, species identification is required using various techniques such as 
polymerase chase reaction (PCR), immunofluorescence, or immunohistochemistry, 
although antibodies for these assays are not commercially available (62, 66, 86). 
Serology  
Serology is the most common tool used to indirectly determine the presence or 
absence of an organism within a herd due to its low cost and the ease of sample 
collection. However, as with most diagnostic assays associated with M. hyopneumoniae 
infection, interpretation of serological results may be challenging. Currently, many 
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producers are interested in eliminating M. hyopneumoniae from their herds, but several 
characteristics of M. hyopneumoniae make this difficult to achieve and maintain. 
Seroconversion after infection often takes four to eight weeks to achieve. When this trait 
is combined with the often slow spread of M. hyopneumoniae within a herd it makes 
accurate and timely diagnosis within individual animals difficult. This complicates the 
use of serology as a reliable screen for replacement animals.  
Current M. hyopneumoniae ELISAs include the Tween-20 ELISA (8, 61)  and the 
HerdChek® M. hyopneumoniae Antibody Test Kit (IDEXX Laboratories, Westbrook, 
ME), which are both indirect ELISAs. The IDEIA™ M. hyopneumoniae EIA KIT 
(Oxoid, Ely, Cambridgeshire, UK, which is formerly the DAKO M. hyopneumoniae 
ELISA) is a competitive-inhibition ELISA. The antibodies detected in the indirect assays 
recognize numerous proteins primarily associated with the cell membrane, while the 
Oxoid ELISA is designed to detect antibodies to a single intracellular protein of M. 
hyopneumoniae. Each of these strategies has advantages and limitations.  
Antigenic variability between isolates of M. hyopneumoniae has been documented (6, 
14) and recent studies indicate that the current ELISAs vary in their ability to detect 
antibodies from pigs experimentally infected with different field isolates of M. 
hyopneumoniae (92, 101). Using western blot analysis, Ameri, et al. found pigs in the 
field develop different antibody profiles after natural infection with M. hyopneumoniae 
(1). In his study, Ameri divided the sera into categories including samples negative by the 
competitive inhibition ELISA (DAKO), but positive by an indirect ELISA (IDEXX), and 
vice versa. The findings from this study suggest that not all pigs produce antibodies to the 
single protein used in the competitive inhibition ELISA. An assay based on more than 
one protein may decrease the likelihood of false-negative results. 
Previous studies have found both the competitive-inhibition and indirect ELISAs to 
be highly specific to M. hyopneumoniae (20, 85) although false-positive results from sera 
with a high titer to M. flocculare by the Tween 20 indirect ELISA has been described (8). 
These findings increase concerns of potential false-positive results in the indirect ELISAs 
which use whole-cell extracts of cultured M. hyopneumoniae as antigen. 
Polymerase-chain reaction.  
A number of PCR assays have been developed and reported to be both sensitive and 
specific for M. hyopneumoniae (9, 13, 19, 38, 46, 85, 86, 89, 90, 100). As a result, this 
technique is now among the most widely used for detection of M. hyopneumoniae in pigs. 
While the development of PCR assays has greatly enhanced our ability to detect M. 
hyopneumoniae, genetic variability among different isolates has been demonstrated (2, 
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17, 41, 47, 49, 87). It is not known to what extent this heterogeneity affects the sensitivity 
of the different assays. Even though the genome of three different strains of M. 
hyopneumoniae have been sequenced (55, 99), there is little data available concerning 
which genes are conserved among M. hyopneumoniae field isolates. A recent study found 
that in order to increase the detection of M. hyopneumoniae on Swiss farms, two PCR 
assays specific for different genes were required in order to detect all of their M. 
hyopneumoniae field samples (19).  
Mycoplasma hyopneumoniae colonizes the lower respiratory tract; therefore, nasal 
swabs for PCR analysis are only moderately sensitive unless the pigs are actively 
shedding the organism through coughing. One study evaluated the use of 
polyethersulfone membranes (pore size, 0.2 micron) mounted in filter holders for air 
sampling in swine confinement buildings (89). Under field conditions, the sampling 
system was able to detect airborne M. hyopneumoniae on 80% of farms where acute 
respiratory disease was present. No airborne M. hyopneumoniae was detected on infected 
farms that did not have acute cases. Samples obtained from bronchoalveolar lavage fluid 
and tracheobronchial sites have been shown to be the most predictive of infection (38).  
Summary with Hypothesis and Goals  
While M. hyopneumoniae remains as an important and wide-spread pathogen in 
today’s swine industry, little is understood in the way of virulence factors used by the 
organism or protective mechanisms needed in the host. It is also unknown what impact 
variation between field isolates at the genetic and protein expression levels have on 
virulence, detection or protection. This is largely due to the fastidious nature and unique 
genetics of M. hyopneumoniae that have hindered detailed study of the organism.  
The overall hypothesis of this study is that field isolates of M. hyopneumoniae that 
are distinct by genetic and/or protein analysis possess a range of virulence and will not be 
equally detected through PCR or ELISA, nor will current vaccines be equally protective. 
Therefore the goal of the research performed in this group of studies is to evaluate the 
ability of different isolates of M. hyopneumoniae to cause disease and also to determine if 
currently used diagnostic assays and protective measures are affected by differences 
between isolates of M. hyopneumoniae from the field. 
The first experiment described in Chapter 2 involves challenging pigs with four 
different field isolates of M. hyopneumoniae and comparing them to pigs infected with a 
traditional challenge strain, 232. Macroscopic pneumonia was measured in each pig at 
necropsy and compared between groups. In addition, growth characteristics of the 
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isolates in vitro and in vivo and cytokine expression were analyzed and correlated to 
virulence.  
The next two chapters evaluated whether genetic or antigenic variation within isolates 
of M. hyopneumoniae affected the detection ability of currently used diagnostic assays. 
Chapter 3 evaluated the ability of currently used M. hyopneumoniae-specific PCR assays 
to detect a panel of M. hyopneumoniae isolates. In addition, two new real-time PCR 
assays were developed that appear to be sensitive and specific for M. hyopneumoniae. In 
Chapter 4 a time-course study was undertaken to acquire serum from pigs challenged 
with four different isolates of M. hyopneumoniae, two isolates of M. flocculare and one 
isolate each of M. hyorhinis and M. hyosynoviae in order to test the sensitivity and 
specificity of currently used M. hyopneumoniae-specific ELISAs. 
In Chapter 5 pigs were either vaccinated with a commercially-available vaccine or 
given a saline injection. Then half of the pigs in each treatment group were challenged 
with one of two different virulent field isolates of M. hyopneumoniae and then evaluated 
for the ability of the vaccine to protect against disease. Pigs were evaluated for 
macroscopic pneumonia, local and systemic antibody production and organism level in 
the lungs. 
The dissertation concludes with a summary of General Conclusions and Future 
Studies. Genetic and proteomic differences between field isolates of M. hyopneumoniae 
impact the ability of different isolates to cause disease, and be detected and protected 
against. No clear traits have been definitively correlated to specific virulence factors in 
high versus low pathogenic isolates. This is the goal of future studies using both genetic 
(microarray) and proteomic (MALDI-TOF) technologies. 
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Abstract 
In vivo and in vitro characteristics associated with four field isolates of Mycoplasma 
hyopneumoniae and strain 232 were compared in a challenge study. Pigs were intratracheally 
inoculated on three consecutive days with log-phase culture of one of the isolates, or on one 
day with lung homogenate containing strain 232. Virulence was measured as the ability to 
induce macroscopic lung lesions. Virulence was then correlated to immunoglobulin (Ig)A 
and IgG levels in bronchial alveolar lavage fluid (BALF), interleukin (IL) 1ß and IL-18 
cytokine levels in BALF, and to in vitro and in vivo growth characteristics. In addition, serum 
antibody levels were tested using three different M. hyopneumoniae-specific ELISAs: the 
Tween 20 ELISA, the HerdChek® Mycoplasma hyopneumoniae ELISA (IDEXX 
Laboratories, Westbrook, Maine), and the IDEIA™ M. hyopneumoniae EIA KIT (Oxoid, 
Ely, Cambridgeshire) to compare the sensitivity of these assays. In this study significant 
differences in the amount of macroscopic pneumonia were produced between the challenge 
groups, but no trait was identified that significantly correlated to the level of virulence 
observed in the isolates. The Oxoid ELISA was the most sensitive assay for detecting 
antibodies in serum tested at 28 days-post-challenge (DPC). The Tween 20 and IDEXX 
ELISAs detected fewer positive results at 28 DPC and had discrepant results between the two 
assays in 34% of these samples. This study confirmed variations in virulence among field 
isolates and suggests differences in the ability of ELISA assays to detect antibodies raised 
isolates of M. hyopneumoniae in the field. 
1. Introduction 
Mycoplasma hyopneumoniae is widely considered to be one of the most important 
pathogens affecting pigs today (Holtkamp, 2007). As a primary pathogen, M. hyopneumoniae 
produces a bronchopneumonia characterized by peribronchiolar and perivascular lymphoid 
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hyperplasia with high morbidity and low mortality. More importantly, M. hyopneumoniae 
combines with other bacteria and viruses to form the porcine respiratory disease complex.  
A previous study by Vicca, et al. (2003) identified field isolates of M. hyopneumoniae with 
high, moderate or low virulence, but traits correlating with virulence remain poorly defined. 
Vicca, et al. (2003) identified a 5,000 base pair fragment by randomly amplified polymorphic 
DNA (RAPD) analysis that appeared to be associated with more virulent strains, but no 
function has yet been assigned to this fragment. Using one high virulent and one low virulent 
isolate from the Vicca collection (Vicca et al., 2003) in a challenge study using cesarean-
derived, colostrum-deprived (CD/CD) pigs, Meyns, et al. (2007) reported increased virulence 
associated with faster in vitro growth, an enhanced capacity to multiply in the lungs, the 
ability to induce increased inflammatory cytokines interleukin (IL)-1ß and TNFα and attract 
increased numbers of neutrophils in the lungs. These associations were made using only two 
isolates; therefore, more isolates need to be studied to determine if these correlations apply in 
general. This study sought to compare virulence among isolates of M. hyopneumoniae by 
experimentally challenging pigs using culture of four recent field isolates, or a well-
established model using lung homogenate from strain 232 which derives from M. 
hyopneumoniae strain 11 (Ross et al., 1984; Thacker et al., 1999; Thacker et al., 2000a). The 
four M. hyopneumoniae field isolates used in this study have been previously shown to be 
genetically distinct from each other and from strain 232 (Madsen et al., 2007).  
Necropsies were performed at 28 days-post-challenge (DPC) and virulence was assessed 
by comparing macroscopic lung lesions. The inflammatory cytokines IL-1ß and IL-18, 
previously shown to be increased during M. hyopneumoniae infection were measured in 
bronchial alveolar lavage fluid (BALF) (Asai et al., 1993; Lorenzo et al., 2006; Meyns et al., 
2007; Muneta et al., 2006). In addition from BALF, immunoglobulin (Ig)A and IgG levels 
were measured by ELISA (Thacker et al., 2000b), and organism level was determined by 
real-time PCR.  
Serum collected prior to challenge and at necropsy 28 DPC was tested using three 
different M. hyopneumoniae-specific ELISAs: the Tween 20 ELISA(Bereiter et al., 1990), 
the HerdChek® Mycoplasma hyopneumoniae ELISA (IDEXX Laboratories, Westbrook, 
Maine), and the IDEIA™ M. hyopneumoniae EIA KIT (Oxoid, Ely, Cambridgeshire) to 
compare the sensitivity of these assays.  
In addition, in vitro growth characteristics were compared using real-time PCR to 
generate growth curves. The in vitro growth rates and capacity to stimulate an immune 
response measured by local cytokine and immunoglobulin levels were correlated to 
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macroscopic pneumonia in order to identify traits related to increased virulence in field 
isolates of M. hyopneumoniae. 
2. Materials and Methods 
2.1. Mycoplasma hyopneumoniae field isolates 
Mycoplasma hyopneumoniae isolates: 95MP1505, 95MP1505, 00MP1301, and 
00MP1502 were isolated from pigs presented to the Iowa State University Veterinary 
Diagnostic Laboratory for necropsy. Tissue was aseptically collected at the leading edge of 
lesions from lungs of pigs with pneumonia characteristic of M. hyopneumoniae. The lung 
tissue was ground in Friis media (Friis, 1975) and inoculated by 10-fold dilution into a series 
of culture tubes with Friis media. Cultures indicating growth by turbidity and acid change in 
the media were confirmed as M. hyopneumoniae using a previously published multiplex PCR 
assay (Stakenborg et al., 2006).   
2.2. Study design 
Thirty-eight 10-to 12-day-old pigs from a farm serologically negative for M. 
hyopneumoniae, porcine reproductive and respiratory syndrome virus and swine influenza 
virus were divided into five challenge groups of seven pigs and one negative control group of 
three pigs. Groups were individually housed in separate rooms in a biosecure animal holding 
facility at Iowa State University and fed ad libitum throughout the study. The four groups 
challenged with the field isolates were inoculated on three consecutive days (0 DPC, 1 DPC  
and 2 DPC) with 10 ml of log-phase culture media as determined by turbidity and an 
acidification of the media to approximately pH 6.8 (Zielinski and Ross, 1990). Cultures for 
isolates 00MP1301 and 00MP1502 were at passage six on challenge days one and two and 
passage seven for challenge day three. Cultures for isolates 95MP1505 and 95MP1509 were 
at passage eight on challenge days one and two and passage nine for challenge day three. The 
group receiving M. hyopneumoniae strain 232 was inoculated on 0 DPC with 10 ml of 
diluted lung homogenate as previously described (Ross et al., 1984). Color-changing unit 
(CCU) titers for each inoculum were determined each challenge day as previously described 
(Stemke and Robertson, 1982). The negative control group received no treatment. Pigs in all 
groups were necropsied at 28 DPC. All animal procedures and care were conducted under the 
supervision and regulations of the Iowa State University Institutional Animal Care and Use 
Committee. 
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2.3. Sample collection 
Blood was collected for serum at 0 DPC and at necropsy, 28 DPC. Lesions consistent 
with mycoplasmal pneumonia were sketched on a standard lung diagram then analyzed for 
the proportion of affected lung using a Zeiss SEM-IPS image analysis system (Ross et al., 
1984). Bronchial alveolar lavage fluid (BALF) was collected from each pig using 50 ml of 
sterile phosphate-buffered saline (PBS), pH 7.2 (1.54mM KH2PO4, 155.17mM NaCl, and 
2.71mM Na2HPO4-7H20) as previously described (Mengeling et al., 1995). After collection, 
the BALF was divided into 1 ml aliquots and frozen at -80ºC until assayed by quantitative 
real-time PCR and cytokine ELISAs as described below. Bronchial swabs were collected for 
mycoplasma isolation and also for routine bacterial culture.  
2.4. Serology 
Three ELISA’s for M. hyopneumoniae antibody detection: the Tween 20 (Bereiter et al., 
1990), the HerdChek® Mycoplasma hyopneumoniae ELISA, and the IDEIA™ M. 
hyopneumoniae EIA KIT were used to measure antibodies to M. hyopneumoniae at 0 and 28 
DPC. The Tween 20 was performed as previously described (Bereiter et al., 1990) and the 
IDEXX and Oxoid ELISAs were performed as per manufacturer’s instructions.   In the 
Oxoid ELISA, a sample is defined as positive if the percent inhibition of the sample is ≤ 50% 
of the buffer control. Samples with an OD > 50% of the buffer control are defined as 
negative. The IDEXX assay presents results as a S:P ratio which is calculated as: (sample OD 
– negative control OD) ÷ (positive control OD – negative control OD). A S:P ratio ≥ 0.4 is 
positive; < 0.4, ≥ 0.3 is suspect; and < 0.3 is negative. For the Tween 20 ELISA, all samples 
are tested in duplicate and the average optical density (OD) of the two is used. The positive 
control is normalized to an OD of 0.4, and the samples are then adjusted accordingly. Optical 
densities ≥ 0.24 are defined as positive. Negative results are defined as OD < 0.2, and an OD 
< 0.24, ≥ 0.2 is defined as suspect.  
2.5. BALF analysis 
To quantify the number of Mycoplasma hyopneumoniae organisms in the lungs, a real-
time PCR was performed on a 1 mL aliquot of BALF from each pig. The BALF was 
centrifuged at 16,000 xg for 10 minutes, and the resulting pellet was resuspended in 200 µl of 
PBS. DNA was isolated using the QIAamp DNA mini kit (Qiagen, Valencia, California) as 
per manufacturer’s instructions. In addition, DNA was isolated from M. hyopneumoniae 
strain 232 by phenol-chloroform extraction (Sambrook and David, 2001) for use in 
generating a standard curve for quantitative analysis. A real-time PCR assay targeting the 
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mhp183 gene of M. hyopneumoniae was performed as previously described (Strait et al., 
submitted). 
Commercially available immunoassays for IL-1ß and IL-18 (BioSource™ Swine 
Immunoassay Kit, Invitrogen, Carlsbad, CA) were performed on BALF as per 
manufacturer’s instructions including quantification by standard curve. M. hyopneumoniae-
specific IgA and IgG antibodies were measured using a previously described assay (Thacker 
et al., 2000b). 
2.6. Growth curves 
A quantitative real-time PCR targeting the gene mhp183 (Strait, et al., submitted) was 
used to generate a growth-curve for each M. hyopneumoniae isolate. Tubes containing 5 ml 
of Friis media were inoculated with 500 µl of log-phase culture from each isolate. For the 
growth-curve, 200 µl samples were collected at multiple time-points over a 96 hr period. The 
DNA from each culture was extracted as described above using the QIAamp DNA mini kit, 
and then assayed using the mhp183 real-time PCR. A standard curve was generated using 
phenol-chloroform extracted DNA from strain 232 (Sambrook and David, 2001). 
2.7. Statistics 
Statistical differences between groups were analyzed using Analysis of Variance 
(ANOVA) on data including percentage of lung lesions, IgA and IgG ELISA antibody levels, 
IL-1ß and IL-18 ELISA cytokine levels, and organism levels measured by quantitative real-
time PCR. Least significant differences (LSD) were calculated to compare means. All 
analyses were considered significant at p < 0.05. 
3. Results 
3.1. Challenge inoculum titers 
Titration of each inoculum was performed on each day of challenge. The inoculum used 
for the four field isolates were log-phase cultures and the challenge procedure was performed 
on three consecutive days. Their average titers were as follows: 107.3 CCU/ml for strain 
95MP1505; 107.2 CCU/ml for strain 95MP1509; and 104.2 CCU/ml for strains 00MP1301 and 
00MP1502. Pigs challenged with strain 232 were given diluted lung inoculum once at a titer 
of 104 CCU/ml.  
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3.2. Percent pneumonia 
All pigs in the M. hyopneumoniae challenge groups produced lesions characteristic of 
mycoplasmal pneumonia, while the negative controls had no visible signs of pneumonia 
(Figure 2.1 and Table 2.1). The percentage of pneumonia caused by isolate 95MP1509 was 
significantly higher than was caused by isolates, 00MP1502 or strain 232. The percentage of 
pneumonia caused by isolate 00MP1301 was significantly greater than observed with isolate 
00MP1502. 
 
 
Figure 2.1. Box-plot comparing the percent of macroscopic pneumonia in pigs challenged 
with one of four field isolates of M. hyopneumoniae, strain 232, or unchallenged controls. 
Groups indicated by different lower-case letters are significantly different from each other,  
p < 0.05. *Denotes an outlier that was excluded from the statistical analysis. 
3.3. Bacterial isolation 
Mycoplasma hyopneumoniae was isolated from bronchial swabs collected at necropsy 
from all pigs in the groups challenged with isolates 95MP1505, 00MP1502, and strain 232. 
In the group challenged with isolate 00MP1301, 6/7 pigs cultured positive for M. 
hyopneumoniae, while 4/7 pigs cultured positive in the 95MP1509 group. Streptococcus suis 
was cultured from 2 pigs in each of the 00MP1301 and 95MP1509 groups, but no disease 
was found to be associated with these infections. 
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Table 2.1. Summary of pneumonia and bronchial alveolar lavage fluid analysis at 28 DPC.  
GROUP 
PIG 
ID 
Pneumonia 
(%) PCR (ng/ul) 
IL-1B 
(pg/ml) 
IL-18 
(pg/ml) 
IgA 
(OD)  
IgG 
(OD) 
410 1.19 0.004 0 0 0.18 0.004 
411 2.72 0.193 10.37 0 0.432 0.011 
420 1.15 0.032 3.44 0.11 0.044 0 
421 0.44 0.148 0 0 0.205 0.037 
429 8.57 2.012 0.12 0 0.287 0.105 
432 11.01 3.664 7.59 23.39 0.331 0.076 
232 438 14.22 0.926 24.55 0 0.347 0.192 
407 10.58 1.005 17.08 0 0.464 0.126 
412 14.08 2.301 1.71 0 0.638 0.195 
417 5.22 1.152 0 0 0.611 0.146 
418 7.79 1.743 0 0 0.57 0.18 
427 1.21 1.372 0 0 0.39 0.023 
431 17.47 3.727 9.83 0.55 0.529 0.488 
00MP1301 437 20.30 2.860 3.17 0 0.424 0.262 
409 4.96 3.619 0 0 0.403 0.106 
413 4.83 1.623 9.92 4.50 0.36 0.039 
414 7.32 2.866 0 0 0.446 0.105 
416 6.74 5.263 3.49 0 0.397 0.27 
430 10.20 1.427 6.68 0 0.192 0.332 
433 7.39 1.292 110.67 94.11 0.383 0.132 
95MP1505 434 24.42 2.559 45.48 110.02 0.552 0.627 
406 6.61 1.623292 7.27 0 0.633 0.092 
415 10.11 0.71398 21.59 0 0.571 0.216 
422 5.92 0.890401 9.42 13.35 0.691 0.211 
423 10.96 0.827501 0.89 0 0.637 0.115 
425 9.87 0.443709 0 0 0.673 0.208 
436 29.88 5.060982 2.99 0 0.467 0.372 
95MP1509 439 21.13 4.664796 26.60 155.21 0.566 0.207 
404 0.75 1.163191 32.85 21.30 0.438 0.015 
405 2.54 0.392438 7.78 12.20 0.695 0.304 
419 2.08 1.068819 2.76 0 0.377 0.037 
424 2.06 4.434803 0.85 0 0.577 0.21 
426 6.73 5.060982 38.14 37.21 0.363 0.169 
428 34.20 10.627708 42.512 16.797 0.372 0.387 
00MP1502 435 1.48 2.612066 67.54 37.68 0.501 0.233 
402 0.00 0 0 0 0 0 
403 0.00 0 0.755 0 0.048 0 
control 408 0.00 0 6.818 0 0 0 
ID = individual pig identification; OD = optical density.  
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3.4. Quantitative real-time PCR 
Real-time PCR was used to quantify the number of M. hyopneumoniae organisms in the 
lungs of pigs at necropsy by BALF analysis. A summary of these results is in Table 2.1. No 
significant difference in the number of organisms in BALF was found between any of the 
challenge groups.  
3.5. IL-1ß and IL-18 ELISAs  
Quantitative cytokine ELISAs measuring IL-1ß and IL-18 in BALF were performed. 
Results from these assays are presented in Table 2.1. No significant difference in either 
cytokine was found between any of the groups, including the negative controls.  
3.6. IgA and IgG ELISAs 
Immunoglobulin A and IgG ELISAs were performed on BALF from each pig (Table 
2.1). No significant difference in either immunoglobulin was found between any of the 
challenge groups, but all had significantly more IgA antibodies than the negative control 
groups (p<0.0001). For IgG antibodies, the difference between the challenged and 
unchallenged groups approached significance (p=0.0538). 
3.7. Serology 
All pigs were seronegative prior to challenge and the control group remained negative 
throughout the trial as measured by all three ELISA’s. At 28 DPI, the Oxoid ELISA found all 
pigs positive except for one pig that was negative. Overall, the IDEXX assay detected 40% 
of the samples as positive, 43% as negative and 17% as suspect, while the Tween 20 assay 
detected 46% samples as positive, 46% as negative and 8% as suspect. A direct comparison 
between the Tween 20 and IDEXX ELISAs showed that 12/35 of the results from individual 
pigs were discrepant between these two tests (Table 2.2). 
3.8. Growth curves 
A comparison of growth curves for each of the four field isolates and strain 232 is shown 
in Figure 2.2. Isolates 95MP1505, 00MP1502 and 00MP1301 grew to the highest titer while 
isolate 95MP1509 and strain 232 had the lowest titers. Isolates 95MP1505 and 95MP1509 
reached their maximum titer more quickly than did the other cultures.  
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Table 2.2. A comparison of Tween 20, IDEXX and Oxoid ELISA results from sera collected 
at necropsy (28 DPC) from pigs challenged with one of four field isolates of M. 
hyopneumoniae or strain 232.  
 
Challenge 
group ELISA Pig replicates (7/group) 
232 Tween 20 - - - - +/- + + 
 IDEXX - - - - - - + 
 Oxoid + + - + + + + 
00MP1502 Tween 20 - - - - - + + 
 IDEXX - - - - +/- +/- + 
 Oxoid + + + + + + + 
00MP1301 Tween 20 - - +/- +/- + + + 
 IDEXX - +/- +/- + - - + 
 Oxoid + + + + + + + 
95MP1505 Tween 20 - - - + + + + 
 IDEXX - - +/- + + + + 
 Oxoid + + + + + + + 
95MP1509 Tween 20 - - + + + + + 
 IDEXX + + +/- + + + + 
  Oxoid + + + + + + + 
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Figure 2.2. Growth-curves for four M. hyopneumoniae field isolates and strain 232 
generated from real-time PCR on culture samples.  
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4. Discussion 
The results of this study confirm previous findings demonstrating a range of virulence 
between field isolates of M. hyopneumoniae measured at 28 DPC. In the current study no 
single measure of the immune response in pigs, or growth characteristics of the organism in 
vivo or in vitro was predictive for level of virulence in the field isolates. This is in contrast to 
the study by Meyns, et al. (2007) that found a correlation of increased virulence to faster in 
vitro growth, increased organism level and numbers of neutrophils in the lungs, and the 
ability to induce the inflammatory cytokines IL-1ß and TNFα (Meyns et al., 2007). The study 
by Meyns et al. (2007) compared a highly virulent isolate of M. hyopneumoniae to an isolate 
cultured from a herd with no clinical signs using CD/CD pigs. In the current study 
conventional pigs were used and the isolates for challenge were obtained from clinical cases 
submitted for necropsy at the Iowa State University Veterinary Diagnostic Laboratory. 
Therefore, the difference in virulence between the groups was less pronounced than in the 
studies comparing field isolates of M. hyopneumoniae cultured from herds with varying 
disease profiles (Meyns et al., 2007; Vicca et al., 2003).  
As is common in M. hyopneumoniae challenge studies, considerable pig-to-pig variation 
was observed within each group and statistical significance when comparing lung lesions was 
achieved only after an outlier from group 00MP1502 was removed from the analysis. 
Similarly, the combination of small group numbers and individual variation impeded 
statistical analysis of IL-1ß and IL-18 cytokine levels, and IgA and IgG antibody levels in 
BALF. It is unclear why IL-18 cytokine levels were not detected in over half of the BALF 
samples as this cytokine has been demonstrated at high levels by ELISA and 
immunohistochemistry at 28 DPC in a previous study (Muneta et al., 2006). Perhaps the 
ELISA used in the current study was less sensitive, or peak levels of secretion occurred at an 
earlier time-point. 
Mycoplasma hyopneumoniae forms small, difficult to count colonies on agar; therefore, 
quantification using standard bacterial culture methods is not possible. Instead, a quantitative 
real-time PCR targeting the mhp183 gene of M. hyopneumoniae was used to generate a 
growth-curve for each M. hyopneumoniae isolate in this study. The growth curves and 
quantitative real-time PCR assay measuring organism level in the lung in the current study 
failed to support the findings by Meyns, et al. (2007) that correlated enhanced growth 
characteristics in vitro and in vivo measured using the CCU method with increased virulence. 
Additionally, differences in CCU titers of challenge inoculum in this study did not correlate 
to lung lesions at necropsy. Whereas inoculum for isolates 95MP1505 and 95MP1509 had 
CCU/ml titers 1000-fold higher than isolates 00MP1301 and 00MP1502 and strain 232, 
 32 
isolates 95MP1509 and 00MP1301 induced the highest amount of lung lesions and 
95MP1505, 00MP1502 and strain 232 induced the lowest percentage of lesions.  
The three ELISA’s for M. hyopneumoniae antibody detection tested in this study differed 
in their sensitivity for antibodies produced against the different M. hyopneumoniae isolates. 
Previous comparisons of these ELISAs have relied on field sera or sera from pigs challenged 
only with strain 232 (Ameri-Mahabadi et al., 2005; Erlandson et al., 2005). No other 
experiments have previously compared sera of known status from pigs infected with different 
isolates of M. hyopneumoniae. At 28 DPC every challenged pig except one was positive by 
the Oxoid™ ELISA. While the IDEXX and Tween 20 ELISAs produced similar numbers of 
positive, negative and suspect results overall when compared to each other, each produced 
fewer positives from challenged pigs at 28 DPI compared to the Oxoid ELISA as has been 
previously demonstrated (Erlandson et al., 2005). Although when the IDEXX and Tween 20 
ELISAs were compared on an individual pig basis they disagreed 34% of the time. Both the 
IDEXX and Tween 20 ELISAs are produced based on the same methodology (Bereiter et al., 
1990) with the strain of M. hyopneumoniae used for antigen production as the primary 
difference between the two assays. Therefore, the degree of individual variation in results 
between these two assays is somewhat unexpected. The differences between the two indirect 
ELISAs leading to the discrepant results was not identified in this study. 
The results of this challenge study confirm that differences in virulence exist among field 
isolates of M. hyopneumoniae compared at 28 DPC. More studies using a wide range of field 
isolates using larger challenge groups are required to identify traits that correlate with level 
of virulence. The impact of antigenic differences between field isolates of M. hyopneumoniae 
on serology results also warrants further investigation. 
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Abstract 
Mycoplasma hyopneumoniae is an important cause of pneumonia in pigs around the 
world, but confirming its presence (or absence) in pigs can be difficult. Culture for diagnosis 
is impractical, and seroconversion is often delayed after natural infection, limiting the use of 
serology. Numerous PCR assays for the detection of M. hyopneumoniae have been developed 
targeting several different genes. Recently, genetic diversity among strains of M. 
hyopneumoniae has been demonstrated. The effect of this diversity on the accuracy and 
sensitivity of the M. hyopneumoniae PCR assays could result in false-negative results in 
current PCR tests. In this study a panel of isolates of M. hyopneumoniae, Mycoplasma 
flocculare, Mycoplasma hyorhinis and Mycoplasma hyosynoviae were tested with a number 
of M. hyopneumoniae-specific PCR assays. Some M. hyopneumoniae PCR assays tested did 
not detect all isolates of M. hyopneumoniae. To increase efficiency of PCR testing, two new 
real-time PCR assays were developed that are specific and detect all of the M. 
hyopneumoniae isolates used in this study. 
Introduction 
Mycoplasma hyopneumoniae is the causative agent of enzootic pneumonia and an 
integral component of the porcine respiratory disease complex (PRDC). Considered one of 
the most important sources of disease-associated losses in swine production, M. 
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hyopneumoniae is also one of the most difficult to detect. This organism is difficult to isolate 
in pure culture because it is easily overgrown by other contaminating bacteria; therefore, 
culture is generally not attempted. In addition, seroconversion to M. hyopneumoniae is often 
slow within a herd and can vary considerably between pigs, making the use of ELISAs less 
effective. A number of PCR assays have been developed and reported to be both sensitive 
and specific for M. hyopneumoniae (4, 6, 11, 19, 20, 22, 24, 26). As a result, this technique is 
now among the most widely used for detection of M. hyopneumoniae in pigs.  
While the development of PCR assays has greatly enhanced our ability to detect M. 
hyopneumoniae, genetic variability of the organism (1, 5, 12, 14, 15, 21) can affect detection 
by PCR. It is not known what affect this heterogeneity has on the sensitivity of the different 
assays. Real-time PCR has many advantages over traditional PCR assays including less time 
to obtain quantitative results and a decrease in environmental contamination. Together, these 
traits make real-time PCR assays preferred in diagnostic and research settings. A real-time 
assay has not yet been described that is based on a conserved target common among isolates 
of M. hyopneumoniae. The two currently published M. hyopneumoniae-specific real-time 
assays had to be used in combination in order to detect all M. hyopneumoniae field samples 
in a Swiss collection of isolates (6). In addition, many of the previously published PCR 
assays were validated using only a small number of mycoplasma isolates. Therefore, the 
objectives of this study were to measure the ability of several M. hyopneumoniae-specific 
PCR assays to detect a collection of isolates of M. hyopneumoniae and also to identify new 
targets for real-time PCR assays for M. hyopneumoniae. 
Materials and Methods 
Mycoplasmas. For this study four panels of commonly isolated mycoplasmas of swine 
were assembled including: 36 isolates of M. hyopneumoniae, 10 isolates of Mycoplasma 
flocculare, and 8 isolates each of Mycoplasma hyorhinis and Mycoplasma hyosynoviae. Also 
included were single isolates of several infrequently identified mycoplasmas and 
acholeplasmas of swine and Mycoplasma bovis from cattle. Clinical samples were obtained 
from pigs experimentally inoculated with different isolates of M. hyopneumoniae as 
previously described (28) and from uninfected control pigs. Samples were obtained 28 days-
post-infection at necropsy (28). Cultures from a number of other swine bacterial pathogens 
were also evaluated (Table 3.1). Genomic DNA was obtained from each of the samples using 
the QIAamp DNA mini kit (Qiagen, Valencia, Calif.).  
PCR assays. A list of currently published PCR assays was identified (Table 3.2). These 
assays were then used to test DNA from each of the isolates in Table 3.1. Some assays were 
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performed as previously published (6, 11, 20) while others (4, 19, 22, 23, 26) were modified 
by substituting Master Amp E buffer (Ambion, Austin, Tex.) for the published buffer with 
their published cycling parameters in reactions consisting of 1x Master Amp E, 0.4 mM of 
each forward and reverse primer, 2.5U Taq (New England Biolabs, Inc., Ipswich, Maine), 
template containing 1-10 ng of DNA, and quantity sufficient of PCR-grade water to a final 
volume of 25 µl. The primer pairs from nested-set PCRs were run as individual assays (not as 
nested sets) to independently evaluate the ability of each primer pair to form products.  
M. hyopneumoniae mhp165 real-time PCR. The primers and probe for a real-time PCR 
assay targeting the mhp165 gene of M. hyopneumoniae (Genbank accession AE017332, M. 
hyopneumoniae 232 complete genome: base pairs 195124-201267) were designed using 
PrimerQuest software (Integrated DNA Technologies, Iowa City, Ia.) (Table 3.3: Mhp165 F, 
Mhp165 R, Mhp165 P). Three isolates of M. hyopneumoniae were sequenced in the region of 
the real-time product to evaluate sequence conservation in M. hyopneumoniae (Table 3.3: 
Mhp165 seqF and Mhp165 seqR). A panel of forward and reverse primers was then designed 
(Table 3.3: Mhp165 F g-a, Mhp165 R t-c, Mhp165 R t-c g-a, Mhp165 R g-a) based on the 
sequence results (Fig. 3.1). The primers were then tested for their ability to detect the isolates 
possessing single nucleotide polymorphisms (SNPs). One set of forward and reverse primers 
(Table 3.3: Mhp165 F and Mhp165 R) was selected and shown to be unique to M. 
hyopneumoniae by BLAST analysis. This set was further tested for specificity using a SYBR 
green assay performed as described by the manufacturer (QuantiTect SYBR® Green PCR 
Kit, Qiagen) with DNA from M. hyopneumoniae, M. flocculare, M. hyorhinis and M. 
hyosynoviae. All real-time assays were performed on a Rotor-Gene RG-3000 (Corbett 
Research, San Francisco, California). A checkerboard assay of primers at 100 nM, 300 nM 
and 900 nM versus probe concentrations at 50 nM, 150 nM and 250 nM was used to optimize 
the real-time protocol using the Universal PCR master mix (Applied Biosystems, Foster City, 
Calif.) according to the manufacturer’s directions. The following cycling parameters were 
used: 50ºC, 2 min; 95 ºC, 10 min; 40 cycles of 95 ºC, 15 sec, then 60ºC, 1 min. Template 
DNA from four different isolates of M. hyopneumoniae was utilized in replicates of the 
checkerboard assay. The detection limit of the finalized assay was tested using a dilution 
series (10 ng/µl to 1 fg/µl) of chromosomal DNA from M. hyopneumoniae strain 232. The 
assay was also compared to a nested PCR targeting the mhp165 gene that includes an inner 
set of primers (8) to a previously published outer set (19) (Table 3.3: Mhp165 outerF, 
Mhp165 outerR; Mhp165 innerF, Mhp165 innerR). Using the GeneAmp PCR core kit 
(Applied Biosystems) the following reaction was employed for both the inner and outer 
  
Table 3.1. Bacteria used in this study. 
No. M. hyopneumoniae isolates Source Year of 
Isolation/Receipt* 
Origin  
1 J ATCC 25934, type strain ATCC   
2 232-2A3 (pig passage strain 11)  Iowa State Univ.  Iowa 
3 37-9 Iowa State Univ. 1989 Kentucky 
4 96MP0001 Iowa State Univ. 1996  
5 96MP0002 Iowa State Univ. 1996  
6 05MP0601 Iowa State Univ. 2005 Colorado 
7 06MP0001D Iowa State Univ. 2006  
8 3-14 Iowa State Univ. 1989 Michigan 
9 00MP1301 Iowa State Univ. 2000 Wisconsin 
10 05MP2301 Iowa State Univ. 2005 Minnesota 
11 95MP1501 Iowa State Univ. 1995 Iowa 
12 95MP1502 Iowa State Univ. 1995 Iowa 
13 97MP0001 Iowa State Univ. 1997  
14 95MP1503 Iowa State Univ. 1995 Iowa 
15 95MP1511 Iowa State Univ. 1995 Iowa 
16 95MP1504 Iowa State Univ. 1995 Iowa 
17 95MP1505 Iowa State Univ. 1995 Iowa 
18 95MP1506 Iowa State Univ. 1995 Iowa 
19 95MP1507 Iowa State Univ. 1995 Iowa 
20 95MP1509 Iowa State Univ. 1995 Iowa 
21 95MP1510 Iowa State Univ. 1995 Iowa 
22 00MP0001 Iowa State Univ. 2000  
23 00MP0002 Iowa State Univ. 2000  
24 00MP0003 Iowa State Univ. 2000  
25 05MP2302A  Iowa State Univ. 2005 Minnesota 
26 05MP2303 Iowa State Univ. 2005 Minnesota 
27 06MP0002 Iowa State Univ. 2006  
28 06MP2501 Iowa State Univ. 2006 Missouri 
29 00MP1502 Iowa State Univ. 2000 Iowa 
30 P-1814-10 C. Armstrong, Pursue Univ. 1982*  
31 P-5398-1 C. Armstrong, Purdue Univ. 1982*  
32 P-5782 C. Armstrong, Purdue Univ. 1982*  
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Table 3.1 Continued.     
33 P-6053-2 C. Armstrong, Purdue Univ. 1982*  
34 P-11318-6 C. Armstrong, Purdue Univ.  1982*  
35 P-12895-2 C. Armstrong, Purdue Univ.  1982*  
36 P-13129-6 C. Armstrong, Purdue Univ.  1982*  
M. flocculare isolates    
1 Ms42 27399, type strain ATCC   
2 94MF1501 Iowa State Univ. 1994 Iowa 
3 93MF0001 Iowa State Univ. 1993  
4 P-6526 C. Armstrong, Purdue Univ. 1982*  
5 P-9020-3 C. Armstrong, Purdue Univ. 1982*   
6 P-10019 C. Armstrong, Purdue Univ. 1982*  
7 P-10020 C. Armstrong, Purdue Univ. 1982*  
8 P-18507-3 C. Armstrong, Purdue Univ. 1982*  
9 Mp611 N. Friis, Denmark 1985*  
10 Mp674 N. Friis, Denmark 1985*  
11 Mp703 N. Friis, Denmark 1985*  
12 02MF1501 Iowa State Univ. 2002 Iowa 
M. hyorhinis isolates    
1 7 R.F. Ross, ISU   
2 SK76C R.F. Ross, ISU   
3 97MR3301 Iowa State Univ. 1997 North Carolina 
4 97MR0001 Iowa State Univ. 1997  
5 06MR0001 Iowa State Univ. 2006  
6 06MR3501 Iowa State Univ. 2006 Ohio 
7 97MR0002 Iowa State Univ. 1997  
8 97MR1501 Iowa State Univ. 1997 Iowa 
9 97MR0003 Iowa State Univ. 1997  
10 04MR0001 Iowa State Univ. 2004  
M. hyosynoviae isolates    
1 S16 R.F. Ross, Iowa State Univ.   
2 91MS0001 Iowa State Univ. 1991  
3 94MS0001 Iowa State Univ. 1994  
4 94MS0002 Iowa State Univ. 1994  
5 95MS0001 Iowa State Univ. 1995  
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Table 3.1 Continued. 
6 95MS0002 Iowa State Univ. 1995  
7 97MS0002 Iowa State Univ. 1997  
8 97MS0003 Iowa State Univ. 1997  
9 91MS0002 Iowa State Univ. 1991  
10 06MS1501 Iowa State Univ. 2006 Iowa 
11 06MS2701 Iowa State Univ. 2006 Nebraska 
12 97MS0001 Iowa State Univ. 1997  
Additional bacteria    
1 Mycoplasma arginini R.F. Ross, Iowa State Univ.   
2 Mycoplasma hyopharyngis  R.F. Ross, Iowa State Univ.   
3 Mycoplasma salivarium R.F. Ross, Iowa State Univ.   
4 Mycoplasma buccale R.F. Ross, Iowa State Univ.   
5 Mycoplasma bovis R.F. Ross, Iowa State Univ.   
6 Acholeplasma granularum  R.F. Ross, Iowa State Univ.   
7 Acholeplasma laidlawii B R.F. Ross, Iowa State Univ.   
8 Actinobacillus pleuropneumoniae R.F. Ross, Iowa State Univ.   
9 Arcanobacter pyogenes R.F. Ross, Iowa State Univ.   
10 Bordetella bronchiseptica R. Griffith, Iowa State Univ.   
11 Haemophilus parasuis R.F. Ross, Iowa State Univ. 1998  
12 Erysipelothrix rhusiopathiae R. Griffith, Iowa State Univ. 1989  
13 Pasteurella multocida (group A) R. Griffith, Iowa State Univ. 1987  
14 Salmonella cholerasuis (group C1)  R. Griffith, Iowa State Univ. 2005  
15 Staphylococcus (pig tonsil) R. Griffith, Iowa State Univ.   
16 Streptococcus suis type 1 R. Griffith, Iowa State Univ. 1986  
17 Streptococcus suis type 2 R.F. Ross, Iowa State Univ. 2005  
*Refers to year isolate was received from outside source. For these isolates, the year of isolation is unknown. 
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Table 3.2. Summary of results for PCR assays tested against M. hyopneumoniae isolates. 
 PCR assays 
M. hyopneumoniae isolates A B C D E F G H I J K L M N O 
J ATCC 25934, type strain + + + - - + + + + + + + + + + 
232-2A3 (pig passage of strain 
11) + + + + + + + + + + + + + + + 
37-9 + + + + + + + + + + + + + + + 
96MP0001 - - - - - + + + + + + + - + + 
96MP0002 + + + - - + + + + + + + + + + 
05MP0601 + + + + + + + + + + + + + + + 
06MP0001D + + + + + + + + + + + + + + + 
3-14 + + + + + + + + + + + + + + + 
00MP1301 + + + + + + + + + + + + - + + 
05MP2301 + + + - - + + + + + + + + + + 
95MP1501 - - - + + + + + + + + + + + + 
95MP1502 + + + + + + + + + + + + + + + 
97MP0001 + + + + + + + + + + + + + + + 
95MP1503 + + + - + + + + + + + + + + + 
95MP1511 + + + + + + + + + + + + + + + 
95MP1504 + + + + + + + + + + + + + + + 
95MP1505 + + + + + + + + + + + + + + + 
95MP1506 + + + + + + + + + + + + + + + 
95MP1507 + + + + - + + + + + + + + + + 
95MP1509 + + + + + + + + + + + + + + + 
95MP1510 + + + + + + + + + + + + + + + 
00MP0001 + + + + + + + + + + + + + + + 
00MP0002 + + + + + + + + + + + + + + + 
00MP0003 + + + + + + + + + + + + + + + 
05MP2302A + + + - - + + + + + + + + + + 
05MP2303 + + + + + + + + + + + + + + + 
06MP0002 + + + + + + + + + + + + - + + 
06MP2501 + + + - - + + + + + + + + + + 
00MP1502 + + + + + + + + + + + + - + + 
P-1814-10 - - - + + + + + + + + + - + + 
P-5398-1 + + + - - + + + + + + + - + + 
P-5782 - - - + + + + + + + + + + + + 
P-6053-2 + + + - - + + + + + + + - + + 
P-11318-6 + + + + + + + + + + + + - + + 
P-12895-2 + + + + + + + + + + + + - + + 
P-13129-6 + + + + + + + + + + + + + + + 
A, REP real-time PCR (6); B, outer nested product (22); C, inner nested product (22); D, ABC real-time 
PCR (6); E, inner nested product (26); F, multiplex assay (20); G, outer nested product (19); H, inner 
nested product (8); I, outer nested product (4, 13); J, inner nested product (4); K, (23); L, outer nested 
product (2, 11); M, inner nested product (11); N, mhp165 real-time PCR (this study); O, mhp183 real-
time PCR (this study).  
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Table 3.3. List of primer and probe sequences used in this study. 
Primer/probe 
name* Sequence 
Product 
size 
Mhp165 seqF 5'-CCGGGCAATTCCAAGAGTTATTCAGG-3'  
Mhp165 seqR 5'-TTTGTGCTTCTAAACTAGGCCCTGC-3' 529 bp 
Mhp165 F 5'-TGCCCAGGATATTTCCGATCCAGA-3'  
Mhp165 R 5'-AGACCTGAAGAACGTGCATGGAGA-3'  
Mhp165 F g-a 5'-TGCCCAAGATATTTCCGATCCAGA-3'  
Mhp165 R t-c 5'-AGACCCGAAGAACGTGCATGGAGA-3'  
Mhp165 R t-c g-a 5'-AGACCCGAAGAACGTGCATGAAGA-3'  
Mhp165 R g-a 5'-AGACCTGAAGAACGTGCATGAAGA-3'  
Mhp165 P 5'-Cy5-GCGATCTCAACAAATACCGGGATTGGT-BHQ_2-3' 132 bp 
Mhp165 outerF 5'-TAGAAATGACTGGCAGACAA-3'  
Mhp165 outerR 5'-GAGGCTTTGATTTTGGAGTC-3' 835 bp 
Mhp165 innerF 5'-GATGCAGCAGGAAACTTAC-3'  
Mhp165 innerR 5'-CTCTGTTATCGGAGTTAG-3' 628 bp 
Mhp183 F 5'-CCAGAACCAAATTCCTTCGCTG-3'  
Mhp183 R 5'-ACTGGCTGAACTTCATCTGGGCTA-3'  
Mhp183 P 5'-6_FAM-AGCAGATCTTAGTCAAAGTGCCCGTG-BHQ_1-3' 90 bp 
* F=forward, R=reverse, P=probe 
 
 
 
AE017332 GAATATGGTC ATCACCAAAC ACTAAATTAT GCCCAGGATA TTTCCGATCC AGATTCAAGT 
AE017244 ********** ********** ********** ********** ********** ********** 
AE017243 ********** ********** ********** ********** ********** ********** 
96MP0001 ********** ********** ********** *****A**** ********** ********** 
95MP1509      ********** ********** ********** *****A**** ********** ********** 
06MP2501      ********** ********** ********** *****A**** ********** ********** 
 
AE017332 ATTATTCTTG ATGCGATCTC AACAAATACC GGGATTGGTT TGCAATCTTT TTATAATTTA 
AE017244 ********** ********** ********** ********** ********** ********** 
AE017243 ********** ********** ********** ********** ********** ********** 
96MP0001 ********** ********** ********** ********** ********** ********** 
95MP1509 ********** ********** ********** ********** ********** ********** 
06MP2501 ********** ********** ********** ********** ********** ********** 
 
AE017332 GATGTTCTAA GAAAATATCT CCATGCACGT TCTTCAGGTC TAGACCTACG AAAAGCAGGG 
AE017244 ********** ********** ********** ********** ********** ***G**G*** 
AE017243 ********** ********** ********** *****G**** *****T**A* ********** 
96MP0001 ********** ********** T********* *****G**** *****T**A* ********** 
95MP1509 ********** ********** ********** ********** *****T**** ********** 
06MP2501 ********** ********** ********** *****G**** *****T**A* **********  
Figure 3.1. Sequence alignment of the mhp165 gene real-time PCR target region for isolates of 
M. hyopneumoniae compared to the consensus sequence from M. hyopneumoniae strain 232 
(AE017332). Forward primer, Probe, Reverse primer, an * indicates homologous sequence.    
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primer, 2.5U Taq, 2 µl template (PCR product from the outer reaction is template for the inner 
“nested” reaction), and quantity sufficient of PCR-grade water to a final volume of 50 µl. The 
same cycling parameters were applied to both the outer and inner reactions: 94ºC, 3 min; 35 
assays: 1x PCR buffer II, 2.5 mM MgCl2, 100 µM each dNTP, 0.4 mM each forward and reverse 
cycles of 94ºC, 1 min, 55ºC, 1 min and 72ºC, 2 min. Products from these reactions were analyzed 
on a 1.5% agarose gel. 
M. hyopneumoniae mhp183 real-time PCR. To identify conserved regions for primer and 
probe design, gene sequences for P97 (mhp183) from 17 different GeneBank records were 
aligned using Vector NTI Advance™ 10 (Invitrogen, Carlsbad, CA) (Fig. 3.2), and primers and 
probes were designed with Primer Express Ver. 2.0.0 (Applied Biosystems) (Table 3.3: Mhp183 
F, Mhp183 R, and Mhp183 P). These primers and probes were shown to be unique to M. 
hyopneumoniae by a BLAST search. They were further tested for specificity with a SYBR green 
assay performed as described by the manufacturer (QuantiTect SYBR® Green PCR Kit, Qiagen) 
with DNA from M. hyopneumoniae, M. flocculare, M. hyorhinis and M. hyosynoviae. A 
checkerboard assay of primers versus probe concentrations was performed as described above. 
Template DNA from four different isolates of M. hyopneumoniae was utilized in replicates of the 
checkerboard assay. This assay was then tested against each of the bacterial DNA samples listed 
in Table 3.1. The detection level of the finalized assay was tested with a dilution series (10 ng/µl 
to 1 fg/µl) of chromosomal DNA of M. hyopneumoniae. 
mhp165 and mhp183 multiplex real-time PCR assay. A dilution series of chromosomal 
DNA of M. hyopneumoniae was tested in the mhp165 and mhp183 real-time PCR assays both 
individually and multiplexed, and with or without an exogenous internal positive control (EIPC) 
(Applied Biosystems) (data not shown). The EIPC was used to control for inhibition in the PCR 
reaction caused by the template sample. Reagents for the EIPC were diluted 2-fold from the 
manufacturer’s suggestion. 
DNA sequencing and analysis. The region of the M. hyopneumoniae genome containing the 
Artiushin et al. PCR target (2) and used by Kurth et al. in the outer pair of a nested PCR reaction 
(11), was sequenced in strains 232, 95MP1509, 95MP1505, 00MP1502, and 00MP1301. The 
location of the PCR target was identified by BLAST analysis of the M. hyopneumoniae genome 
sequence (16) with the sequence in Kurth et al. and was found to include the 5’ end of mhp023 
and most of mhp024.  
Nucleotide sequence accession numbers. The nucleotide sequences in the mhp023-mhp024 
chromosomal regions of strains 95MP1505, 95MP1509, 00MP1301 and 00MP1502 have been 
submitted to the GenBank database under accession numbers XX, XX, XX, and XX, 
respectively. The nucleotide sequences in the mhp165 chromosomal region of strains 
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95MP1509, 96MP0001 and 06MP2501 have been submitted to the GenBank database under 
accession numbers XX, XX, and XX, respectively. 
 
AE017332      GAATTTAGCT TTGCAAAAGA TAGTTCAACT AATCAATATG TAAGTATCCA GAACCAAATT   
AE017244      ********** ********** ********** ********** ********** ********** 
AE017243      ********** ********** ********** ********** ********** ********** 
AY957500      ********** ********** ********** ********** ********** ********** 
AY512905      ********** ********** ********** ********** ********** ********** 
AY512904      ********** ********** ********** ********** ********** ********** 
AY512903      A********* ********** ********** ********** ********** ********** 
AY512902      ********** ********** ********** ********** ********** ********** 
AY512901      ********** ********** ********** ********** ********** ********** 
AY512900      ********** ********** ********** ********** ********** ********** 
AY512899      ********** ********** ********** ********** ********** **********   
AY512898      A********* ********** ********** ********** ********** **********    
AY512897      ********** ********** ********** ********** ********** ********** 
AY512896      ********** ********** ********** ********** ********** ********** 
AY512895      ********** ********** ********** ********** ********** ********** 
AY512894      ********** ********** ********** ********** ********** ********** 
U27294      A********* ********** ********** ********** ********** ********** 
 
AE017332      CCTTCGCTGT TTTTAAAAGC AGATCTTAGT CAAAGTGCCC GTGAAATTTT AGCTAGCCCA 
AE017244      ********** ********** ********** ********** ********** ********** 
AE017243      ********** ********** ********** ********** ********** ********** 
AY957500      *********G ********** ********** ********** ********** ********** 
AY512905      ********** ********** ********** ********** ********** ********** 
AY512904      ********** ********** ********** ********** ********** ********** 
AY512903      ********** ********** ********** ********** ********** ********** 
AY512902      ********** ********** ********** ********** ********** ********** 
AY512901      ********** ********** ********** ********** ********** ********** 
AY512900      ********** ********** ********** ********** ********** ********** 
AY512899      ********** ********** ********** ********** ********** **********   
AY512898      ********** ********** ********** ********** ********** **********    
AY512897      ********** ********** ********** ********** ********** ********** 
AY512896      ********** ********** ********** ********** ********** ********** 
AY512895      ********** ********** ********** ********** ********** ********** 
AY512894      ********** ********** ********** ********** ********** ********** 
U27294      ********** ********** ********** ********** ********** ********** 
 
AE017332      GATGAAGTTC AGCCAGTTAT TAACATTTTA AGATTAATGA AAAAAGATAA TTCTTCTTAT 
AE017244      ********** ********** ********** ********** ********** ********** 
AE017243      ********** ********** ********** ********** ********** ********** 
AY957500      ********** ********** ********** ********** ********** ********** 
AY512905      ********** ********** ********** ********** ********** ********** 
AY512904      ********** ********** ********** ********** ********** ********** 
AY512903      ********** ********** ********** ********** ********** ********** 
AY512902      ********** ********** ********** ********** ********** ********** 
AY512901      ********** ********** ********** ********** ********** ********** 
AY512900      ********** ********** ********** ********** ********** ********** 
AY512899      ********** ********** ********** ********** ********** **********   
AY512898      ********** ********** ********** ********** ********** **********    
AY512897      ********** ********** ********** ********** ********** ********** 
AY512896      ********** ********** ********** ********** ********** ********** 
AY512895      ********** ********** ********** ********** ********** ********** 
AY512894      ********** ********** ********** ********** ********** ********** 
U27294      ********** ********** ********** ********** ********** ********** 
Figure 3.2. Sequence alignment of the mhp183 gene real-time PCR target region for isolates of 
M. hyopneumoniae compared to the consensus sequence from M. hyopneumoniae strain 232 
(AE017332). Forward primer, Probe, Reverse primer, an * indicates homologous sequence.   
 
  
45 
Results 
Mycoplasma PCR assay panel. Assays targeting the 16S ribosomal RNA gene (4, 20, 24) 
and the mhp165 gene (8, 19) positively identified all of the M. hyopneumoniae isolates used in 
this study. However, five of the M. hyopneumoniae-specific PCR assays did not detect every M. 
hyopneumoniae isolate in our collection (Table 3.2). These five assays targeted the following 
three genes: a putative ABC transporter (Genbank accession no. U02537) (6, 26), a repeated 
element (Genbank accession no. AF004388) (6, 22), and a target that spanned the hypothetical 
genes mhp023 and mhp024 (Genbank accession no. AE017332, base pairs 27057-28020) (11). 
With the Kurth et al. PCR assay, some strains of M. hyopneumoniae gave products with the outer 
primers, but failed on the inner primer pair.  
Real-time PCR assays. The SYBR green assay using primers for the mhp165 assay were 
specific only to M. hyopneumoniae, while the primers for the mhp183 assay produced a product 
in both M. hyopneumoniae and M. flocculare. When analyzed on a 3% agarose gel, the product 
in M. flocculare was smaller than the amplicon made in M. hyopneumoniae (data not shown), 
indicating that the targets are not identical in each species. 
The most sensitive combinations of primers and probes among the M. hyopneumoniae 
isolates tested for the mhp165 assay were: 900 nM forward primer, 900 nM reverse primer and 
50 nM probe. Additionally, Mhp165 probes labeled with Cy3 or Cy5 were found to perform 
identically regardless of the label used (data not shown). For the mhp183 assay, the most 
sensitive combination was: 50 nM forward primer, 900 nM reverse primer, 50 nM probe. 
Both of the probe-based real-time PCR assays were specific to M. hyopneumoniae, detected 
all isolates of M. hyopneumoniae in our DNA collection and detected none of those in the M. 
flocculare, M. hyorhinis or M. hyosynoviae panels. In addition, none of the other bacteria tested 
were positive by either of these assays (100% specificity). Clinical samples taken 28 days post 
inoculation from M. hyopneumoniae infected pigs were also tested including nasal swabs, 
bronchial swabs and bronchial alveolar lavage fluid. All samples from all infected pigs were 
positive by both assays except for one nasal swab tested by the mhp183 assay (Table 3.4). 
DNA sequence results. DNA sequence analysis of the Kurth et al. PCR target was 
performed due to the failure of the inner product of the nested PCR to detect some strains of M. 
hyopneumoniae. Sequences from strains 232, 95MP1509, and 95MP1505 are nearly identical 
(data not shown), but sequences from strains 00MP1502 and 00MP1301 show three regions with 
only 80-87% homology to strain 232 and three regions with no significant homology including a 
break in the alignment of 00MP1502 and 00MP1301 to 232 at the site where the forward inner 
primer binds. Sequence of the inner-primer binding regions and a graphical representation of the 
Blast scores are shown in Figure 3.3.  
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Sequence analysis of the 529 base pair region containing the primer binding sites in mhp165 
for five isolates of M. hyopneumoniae identified SNPs in the reverse and/or forward primers, 
while the site of probe binding was found to be homologous (Fig. 3.1). Real-time PCR analysis 
using DNA templates from isolates 96MP0001, 95MP1509, 06MP2501, and 232 was then 
performed using primers including each of the identified SNPs (primers for the 132 bp fragment, 
Table 3.3). Every primer pair was able to detect each isolate tested, but variation in the 
sensitivity among M. hyopneumoniae isolates was observed as a change in the Ct value among 
the different primer pairs (data not shown). 
 
 
Table 3.4. Analysis of clinical samples by real-time PCR. 
 
 mhp165 real-time PCR results mhp183 real-time PCR results 
 No. positive/No. of samples tested No. positive/No. of samples tested 
Challenge isolate NS BS BALF NS BS BALF 
95MP1509   7/7   7/7 
95MP1505   7/7   7/7 
00MP1301 2/2 2/2 9/9 1/2 2/2 7/7 
00MP1502 2/2 2/2 9/9 2/2 2/2 7/7 
95MP1501 2/2 2/2 2/2 2/2 2/2 2/2 
97MP0001 2/2 2/2 2/2 2/2 2/2 2/2 
232   36/36   36/36 
Unchallenged controls     0/33     0/33 
NS = nasal swab; BS = bronchial swab; BALF = bronchial alveolar lavage fluid 
 
 
Detection level. A 10-fold dilution series from 10 ng/µl to 1 fg/µl including two additional 
dilutions of 5 fg/µl and 2.5 fg/µl was made with DNA extracted from M. hyopneumoniae strain 
232. One fg of chromosomal DNA is considered to be approximately one genome equivalent 
(11). The nested-set PCR based on the mhp165 gene detected DNA from the 10 ng/µl to 5 fg/µl 
dilutions. The mhp165 and mhp183 real-time PCR assays each detected DNA from the 10 ng/µl 
to 2.5 fg/µl dilutions (data not shown). 
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Figure 3.3 DNA sequence analysis of the Kurth et al. inner PCR product of strains 00MP1502 
and 00MP1301. A. DNA sequence alignment of strains 232, 00MP1502, and 00MP1301in the 
regions of the inner PCR product primers Mhp3 and Mhp4. Identities are shown by the vertical 
lines. B. Graphical representation of the BLAST alignment of the 00MP1502 and 00MP1301 
inner PCR product strain sequences with strain 232. Gray areas indicate poor or no alignment. 
White regions indicate homology with the percent identity indicated below. The region of the 
inner PCR product is indicated by the double arrow. The outer primers bind outside the indicated 
region, and DNA sequence was not obtained for that part of the chromosome. 
 
Discussion 
Five PCR assays targeting three different genes of M. hyopneumoniae failed to detect all of 
the M. hyopneumoniae isolates in our collection. The two published real-time assays targeting 
the ABC and REP genes did not detect every isolate as had been previously reported (6). 
Additionally, the standard PCR assays on which these two real-time assays were based failed to 
detect the same isolates of M. hyopneumoniae in nearly every case (22, 26). Contrary to 
Dubosson et al. (6) who used the REP and ABC real-time assays in combination to detect all 
isolates in their study, there was one isolate (96MP0001, Table 3.1) in the current study that was 
not detected by either of these PCR assays.  
The Kurth et al. PCR assay, a nested assay targeting a unique hypothetical gene of M. 
hyopneumoniae (11), also failed to detect all isolates. The basis for this failure was genetic 
variability among the isolates resulting in deletions and rearrangements in the mhp024 gene. One 
of the PCR primer-binding sites was missing causing failure in the inner-pair reaction. This 
demonstrates the importance of evaluating each primer-pair individually across multiple isolates 
in nested-set PCR assays.  
Based on these PCR results we developed two new real-time PCR assays. The nested PCR 
assay to the gene mhp165 performed well against our panel of isolates, and therefore this gene 
was selected as a target for one of the new real-time assays. The function of the mhp165 gene 
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has not been identified, but it is a large gene (6140 base pairs) containing zinc finger, 
metalopeptidase, coiled-coiled, transmembrane, secretory signal, and ABC transporter sequence 
motifs. This information is available in the M. hyopneumoniae database 
(http://mycoplasma.genome.uab.edu/). 
A second real-time PCR assay developed in this study targets the gene for the P97 cilium 
adhesin (mhp183). The product of this well-characterized gene is important for adherence of M. 
hyopneumoniae to ciliated epithelium within the respiratory tract (9, 10, 27). Because it is 
thought to be necessary for virulence, this gene is likely to be present in all pathogenic isolates of 
M. hyopneumoniae. Additionally, this gene has been sequenced from a large number of isolates 
allowing identification of conserved regions. While a small target was produced with the M. 
flocculare template using the forward and reverse primer in a SYBR green assay, this product 
did not hybridize to our M. hyopneumoniae-specific probe. When M. flocculare DNA was added 
to a dilution series of M. hyopneumoniae DNA, no affect on sensitivity to the real-time assay was 
found (data not shown).  
Due to the restricted parameters used in primer and probe design programs for real-time PCR 
assays, there is often little choice in the area of the gene that can be targeted. This is particularly 
true for M. hyopneumoniae due to its low G+C content (28.6%)(16). Therefore, even though 
SNPs were identified in the primer binding sites for mhp165, this area was unable to be avoided 
because of probe design issues; however, the internal probe was conserved between these 
isolates. In addition to the SNPs identified in the previously sequenced strains: 232, J and 7228, 
three isolates from the M. hyopneumoniae isolate collection were sequenced and found to contain 
various SNPs in the primer-binding regions. More extensive sequencing of isolates was not 
performed due to the fact that all isolates in our panel were detected by this assay. The observed 
SNPs did have an affect on the sensitivity of the mhp165 assay. This could potentially affect the 
diagnostic ability of the mhp165 assay in the field. Additionally, this assay would not be as 
useful for quantitative comparisons of samples from different isolates as the mhp183 assay 
which appears to be conserved at the primer and probe binding sites. 
Both the mhp165 and mhp183 assays detected M. hyopneumoniae DNA in clinical samples 
collected from groups of pigs experimentally inoculated with M. hyopneumoniae isolates. One 
nasal swab sample was found to be negative by the mhp183 assay from a pig challenged with 
isolate 00MP1301. Performing PCR on samples from nasal swabs has previously been shown to 
have a lower detection rate than samples from bronchial swabs or bronchial alveolar lavage fluid 
(11). The nasal swab sample from the other pig challenged with isolate 00MP1301 and the 
bronchial swabs and bronchial alveolar lavage fluid samples from both pigs were all PCR-
positive demonstrating the ability of the mhp183 assay to detect this isolate. The exogenous 
internal positive control included in the mhp183 assay gave a positive result in the nasal swab 
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sample that was negative (data not shown) indicating no sample inhibition occurred and that the 
negative result was more likely due to the low level of M. hyopneumoniae DNA present in the 
sample. 
The assays targeting the 16S ribosomal RNA gene detected all M. hyopneumoniae isolates 
(4, 20, 24), but many researchers are reluctant to target this gene due to its high level of 
conservation among bacterial species that may lead to false positive results. A number of 
mycoplasmas and related acholeplasmas that have received little research such as M. arginini, M. 
salivarium, M. hyopharyngis, A. laidlawii, and A. granularum and others have been isolated 
from pigs (3, 7, 17, 18). The prevalence of these organisms is unclear as is their potential for 
eliciting false-positive results in 16S-based PCR assays (or in PCR assays targeting other genes).  
Although three strains of M. hyopneumoniae have been sequenced (16, 25), there is little 
known concerning the extent of genetic variability between M. hyopneumoniae isolates, making 
it difficult to identify conserved targets for PCR assays. One recent study has shown a 
considerable amount of genetic diversity among field isolates (12). To improve the diagnostic 
ability to detect field isolates of M. hyopneumoniae, the two real-time PCR assays developed for 
mhp165 and mhp183 were multiplexed. An EIPC was included to control for sample inhibition 
from template contaminants leading to a false negative result. No decrease in sensitivity was 
found when comparing the individual assays to the multiplexed assay. Each of the two real-time 
assays was more sensitive than a nested-set PCR assay to the mhp165 gene (8). 
Noteworthy is the fact that the mhp165 and mhp183 assays described here detected all of the 
isolates tested. This is a significant improvement over previously described real-time PCR 
assays. Results from this study also support previously reported genetic diversity among isolates 
of M. hyopneumoniae. The extent of this variability and its affect on currently used diagnostic 
assays to accurately detect a wide range of M. hyopneumoniae field isolates has yet to be 
determined. The majority of M. hyopneumoniae isolates used in the present study came from 
pigs in the United States. A future study comparing these PCR assays against a more diverse 
international collection of M. hyopneumoniae isolates may be beneficial to further test their 
sensitivity and specificity.  
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Abstract 
The objective of this study was to assess the sensitivity and specificity of three Mycoplasma 
hyopneumoniae-specific ELISAs and examine the effect of field isolate variability on 
detection by the Tween 20 ELISA, the HerdChek® M. hyopneumoniae ELISA (IDEXX 
Laboratories, Westbrook, ME), and the IDEIA™ M. hyopneumoniae EIA KIT (Oxoid, Ely, 
Cambridgeshire, UK, formerly DAKO™ M. hyopneumoniae ELISA). The effect of field 
isolate variability on detection by these assays was also examined. A time-course study was 
performed in groups of pigs challenged with M. hyopneumoniae, Mycoplasma flocculare, 
Mycoplasma hyorhinis or Mycoplasma hyosynoviae. Four groups received one of four 
genetically distinct field isolates of M. hyopneumoniae. Two groups received different 
isolates of M. flocculare, and one group each received M. hyorhinis or M. hyosynoviae. Two 
pigs in each group were necropsied at 28, 70 and 95 days-post-challenge (DPC). All sera 
were tested by the three ELISAs. All three ELISAs were specific for M. hyopneumoniae. The 
Oxoid ELISA was the most sensitive assay, detecting pigs earlier (14 DPC) and more 
consistently than either the Tween 20 or IDEXX ELISAs, which did not detect any positives 
until 28 DPC. The Tween 20 and IDEXX ELISAs overall performed similarly to each other, 
but differed 24% of the time on individual results from 28-95 DPC. In addition, the Tween 
20 and IDEXX ELISAs detected lower levels of antibodies in pigs inoculated with one of the 
M. hyopneumoniae isolates suggesting that differences in antibody production to field 
isolates affects sensitivity in these two ELISAs.  
  
 54 
Introduction 
Mycoplasma hyopneumoniae, the causative agent of enzootic pneumonia of swine, is a 
source of significant economic loss in the swine industry today. It is also a key component of 
the porcine respiratory disease complex. While M. hyopneumoniae is currently ubiquitous in 
the countries where it is found, many producers are working to eradicate this organism from 
their production systems. Therefore there is a need to evaluate the presence of M. 
hyopneumoniae within swine herds. 
Serology is the most commonly used tool to monitor herd status due to its low cost and 
the relative ease of sample collection for these assays. Current M. hyopneumoniae ELISAs 
include the 232 Tween 20 ELISA (made using antigen from M. hyopneumoniae strain 232) 
(4, 14) and the HerdChek® M. hyopneumoniae Antibody Test Kit (IDEXX Laboratories, 
Westbrook, ME), which are both indirect ELISAs, and a competitive-inhibition ELISA: the 
IDEIA™ M. hyopneumoniae EIA KIT (Oxoid, Ely, Cambridgeshire, UK, formerly the 
DAKO™ M. hyopneumoniae ELISA). The antibodies detected in the indirect assays 
recognize numerous antigens primarily associated with the cell membrane, while the Oxoid 
ELISA is designed to detect antibodies to a single intracellular protein of M. hyopneumoniae.  
A number of studies have evaluated the sensitivity and specificity of these three ELISAs 
(1, 7, 8, 18-20). Some of the sera used for these comparisons were field samples, while others 
came from challenge studies. The true infection status of sera collected from pigs in the field 
can not always be demonstrated, making it difficult to definitively measure specificity using 
these samples. Experimentally-derived sera used a previous comparison of these ELISAs to 
each other came from pigs challenged with M. hyopneumoniae strain 232 (7), the isolate that 
the 232 Tween 20 is based upon. While sera from experimentally-challenged pigs can be 
used to compare the sensitivity of the different ELISAs to serum antibodies, they do not 
effectively evaluate the ability of the ELISAs to detect antibodies against a variety of isolates 
of M. hyopneumoniae and do not measure specificity. Previous studies comparing different 
isolates of M. hyopneumoniae using SDS-PAGE and western blots have demonstrated 
diversity in protein expression (3, 17). Some of this variation may be due to alterations in 
post-translational processing of surface antigens (5, 6) In addition, western blot analyses 
demonstrated that pigs develop varying antibody profiles following infection with M. 
hyopneumoniae in the field (2). The effect of M. hyopneumoniae protein variation on the 
ability of ELISAs to detect antibodies in a diagnostic setting is not fully known. 
Pigs are the host for a number of mycoplasmas including Mycoplasma flocculare, 
Mycoplasma hyorhinis and Mycoplasma hyosynoviae. Some concern exists for the potential 
of these mycoplasmas to cause false-positives in M. hyopneumoniae-specific ELISAs, 
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especially M. flocculare which is the most antigenically similar to M. hyopneumoniae (4). As 
a result there is a need to evaluate M. hyopneumoniae-specific ELISAs for their sensitivity 
and specificity using serology from pigs with known infection status in relation to other 
species of mycoplasmas in addition to genetically different field isolates of M. 
hyopneumoniae. The objectives of this study were to evaluate the ability of three serological 
assays to detect antibodies to isolates of M. hyopneumoniae at various time-points following 
infection, and assess their sensitivity and specificity to other mycoplasma species commonly 
found in pigs. The virulence of two of the M. hyopneumoniae isolates used in the current 
study: 00MP1301 and 00MP1502, have been established in a previous study where 
00MP1301 was found to be significantly more virulent than isolate 00MP1502 (21). All four 
of the M. hyopneumoniae isolates in the current study have been compared to strain 232 by 
microarray analysis and found to be genetically unique from 232 and from each other (12). 
Materials and Methods 
Animals, housing and experimental design. Forty-eight, 10-12 day-old pigs obtained 
from a commercial herd negative for M. hyopneumoniae were divided into eight groups of 
six pigs housed in separate rooms in a biosecure animal isolation facility at Iowa State 
University. At approximately one month of age, the pigs were challenged on three 
consecutive days with log-phase culture (10 ml intratracheally for M. hyopneumoniae (16) 
and M. flocculare groups, or 5 ml intranasally for M. hyorhinis and M. hyosynoviae groups). 
Mycoplasma hyopneumoniae and M. flocculare were grown in Friis media (9) in a shaking 
waterbath at 37°C, 50 rpm; M. hyorhinis was grown in BHI media (15), stationary at 37°C; 
and M. hyosynoviae was grown in D-TS media (15), stationary at 37°C. There were four M. 
hyopneumoniae groups (isolates: 95MP1501, 97MP0001, 00MP1301 and 00MP1502), two 
M. flocculare groups (isolates: 94MF1501 and 02MF1501) and one group each of M. 
hyorhinis (isolate: SK76C) and M. hyosynoviae (isolate: 97MS0003). Two pigs were 
necropsied at each of the following time points: 28, 70 and 96 days-post-challenge (DPC). 
One pig in each of the 00MP1301 and 02MF1501groups died from causes unrelated to the 
study; therefore, in these groups one pig rather than two were necropsied at 70 DPC. All 
animal procedures and care were conducted under the supervision and regulations of the 
Iowa State University Institutional Animal Care and Use Committee. 
Sample collection. Pigs were bled up to seven times, depending on their time of 
necropsy at 0, 14, 28, 42, 56, 70 and 96 DPC. Bronchial alveolar lavage fluid (BALF) for M. 
hyopneumoniae PCR analysis was collected from each pig at necropsy using 25 ml of 
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phosphate-buffered saline (PBS), pH 7.2 (1.54mM KH2PO4, 155.17mM NaCl, and 2.71mM 
Na2HPO4-7H20) as previously described (13). Two bronchial swabs were collected from all 
pigs. In addition, two joint swabs from the right hock and left knee joints were collected from 
pigs in the M. hyosynoviae and M. hyorhinis groups. One swab from each sample-type was 
used for routine bacteriological analysis and the other was placed in 1 ml of PBS for PCR 
analysis. Swabs in PBS and BALF were stored at -20ºC prior to DNA extraction.  
Macroscopic pneumonia. At necropsy, lung lesions consistent with M. hyopneumoniae-
induced pneumonia were sketched for each pig onto a standard lung diagram, then analyzed 
for the proportion of affected lung using a Zeiss SEM-IPS image analysis system as 
previously described (16).  
ELISA assays. Serology was performed on all serum samples with the IDEXX and 
Oxoid ELISAs performed as per manufacturer’s instructions and the 232 Tween 20 ELISA 
performed as previously described (4). To determine if the competitive-inhibition ELISA 
manufactured by Oxoid provided the same results as the previous manufacturer (DAKO 
Corporation, Carpenteria, Calif.), all sera were also tested by the DAKO M. hyopneumoniae 
ELISA.  In the Oxoid and DAKO ELISAs, a sample is defined as positive if the percent 
inhibition of the sample is ≤ 50% of the buffer control. Samples with an OD > 50% of the 
buffer control are defined as negative. The IDEXX assay presents results as a S:P ratio which 
is calculated as: (sample OD – negative control OD) ÷ (positive control OD – negative 
control OD). A S:P ratio ≥ 0.4 is positive; < 0.4, ≥ 0.3 is suspect; and < 0.3 is negative. For 
the Tween 20 ELISA, all samples are tested in duplicate and the average optical density (OD) 
of the two is used. The positive control is normalized to an OD of 0.4, and the samples are 
then adjusted accordingly. Optical densities ≥ 0.24 are defined as positive. Negative results 
are defined as OD < 0.2, and an OD < 0.24, ≥ 0.2 is defined as suspect.  
In addition, seroconversion to M. flocculare, M. hyorhinis and M. hyosynoviae was 
evaluated using antigen made to each of these species by the Tween 20 method (4). Briefly, 
each mycoplasma was cultured to log-phase using the medium described above. Mycoplasma 
flocculare strain Ms42 ATCC 27399, M. hyorhinis strain 7, and M. hyosynoviae strain 
97MS0003 cultures were harvested for 45 min at 15,000 xg, and then washed three times 
with PBS. Tween 20 was added at a final concentration of 1% to a 2 mg/ml mycoplasma cell 
suspension (BCA protein assay, Pierce, Rockford, Illinois). The mixtures were incubated at 
37°C for 90 min then harvested at 50,000 xg. The supernatant was passed through a 0.2 µm 
filter. Antigen was coated at a concentration of 10 µg/ml (100 µl/well) in 96-well Immulon 
2HB plates (Thermo electron corp., Milford, MA) overnight at room temperature, then the 
plates were frozen at -80°C until ELISAs were performed following the same steps as for the 
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232 Tween 20 ELISA (4). In addition, the Tween 20 method was used to make ELISA plates 
from M. hyopneumoniae isolate 97MP0001.  
PCR from nasal swabs, bronchial swabs and bronchial alveolar lavage fluid. The 
QIAamp DNA mini kit (Qiagen, Valencia, Calif.) was used for DNA isolation from nasal 
swabs, bronchial swabs, joint swabs and BALF collected throughout the study. The BALF 
was processed as follows: a 1 ml aliquot from each pig was centrifuged at 16,000 x g for 10 
min. The resulting pellet was resuspended in 200 µl of PBS, and then extracted as per 
manufacturer’s instructions. Mycoplasma hyopneumoniae was assayed using a real-time PCR 
targeting the mhp183 gene of M. hyopneumoniae as previously described (Strait et al., 
submitted).  
Western blot assay. A western blot was performed using the Tween 20 ELISA antigen 
prepared for isolate 97MP0001. The antigen was treated in Laemmli sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) reducing buffer.  The SDS-PAGE method 
by Laemmli (11) was followed using a 4% stacking and 10% separating gel. A total of 600 µl 
(300 µg/ml) of antigen was loaded in one large well spanning most of the gel. Separated 
proteins were transferred to a nitrocellulose membrane (Bio-Rad, Hercules, Calif.). The 
membrane was blocked overnight at 4°C in PBS with 1% gelatin from cold water fish skin 
(Sigma, St. Louis, Missouri), then placed in a miniblotter® 25 (Immunetics, Cambridge, 
Mass.) to form individual lanes. To each lane, 250 µl of a 1:40 dilution of serum in PBS with 
0.05% Tween 20 (PBS-T) was added and incubated for 1.5 hr, then washed 3 times with 
PBS-T for 10 min. Serum samples at 0 DPC and 56 DPC from pigs in each of the M. 
hyopneumoniae challenge groups were used (see Figure 4.6). Horseradish peroxidase-labeled 
rabbit anti-swine (MP Biomedicals, Aurora, Ohio) diluted 1:1000 in PBS-T was added and 
incubated for 1 hr, then washed as above. The substrate 4CN (Bio-Rad) was used as per 
manufacturer’s instructions. 
Statistics. The ODs within each ELISA were evaluated by an analysis of variation 
(ANOVA) to determine if there were differences between mean ODs of the groups. Fisher’s 
least significant difference (LSD) was used to compare group means at each time point when 
the ANOVA was significant at a level of p < 0.05.  
 
Results 
Macroscopic pneumonia. Pigs in all of the M. hyopneumoniae challenge groups had 
lung lesions consistent with mycoplasmal pneumonia, primarily at the 28 DPC necropsy 
(Table 4.1). Pigs in groups challenged with M. flocculare, M. hyorhinis or M. hyosynoviae 
had negligible macroscopic pneumonia throughout the study (Table 4.2). 
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Bacteriological findings. Culture results are summarized in Tables 4.1 and 4.2. M. 
hyopneumoniae was isolated from all pigs in each of the four M. hyopneumoniae challenge 
groups at 28 DPC, with fewer M. hyopneumoniae isolations at either 70 or 96 DPC. 
Additionally, M. flocculare was cultured from 5 of 6 pigs in the 00MP1502 M. 
hyopneumoniae challenge group. Mycoplasma flocculare was re-isolated from the two M. 
flocculare groups. In the M. hyosynoviae challenge group M. hyosynoviae was re-isolated 
from one pig, and M. flocculare was found in 5 of 6 pigs in this group. Mycoplasma 
hyorhinis was re-isolated from four pigs in the M. hyorhinis challenge group and these same 
four pigs also had M. hyopneumoniae cultured from them. No other pathogenic bacteria were 
cultured from any pig. 
Oxoid, IDEXX and 232 Tween 20 ELISAs. The Oxoid, IDEXX and 232 Tween 20 
ELISAs detected antibodies in pigs from all four of the M. hyopneumoniae challenge groups 
(Figures 4.1, Table 4.3). All pigs were seronegative for M. hyopneumoniae antibodies prior 
to challenge. Seroconversion occurred as early as 14 DPC in 22 of 24 pigs as measured by 
the Oxoid ELISA, none of the M. hyopneumoniae-infected pigs were seropositive at that 
time-point using the IDEXX or 232 Tween 20 ELISAs. By 28 DPC all pigs in all challenge 
groups were seropositive using the Oxoid ELISA and remained positive until necropsy. 
Alternatively at the 28 DPC time-point, the 232 Tween 20 ELISA detected antibody positive 
or suspect values in 11 of 23 (48%) of the M. hyopneumoniae-infected pigs, while the 
IDEXX ELISA detected antibodies in 16 of 23 (70%) pigs. By 42 DPC both indirect ELISAs 
detected M. hyopneumoniae antibodies in 14 of 15 (93%) of the M. hyopneumoniae-infected 
pigs. Among pigs that were kept longer than 28 DPC, all were found positive at one time 
point by the Oxoid and IDEXX ELISAs, while pig 157, challenged with M. hyopneumoniae 
isolate 97MP0001, remained seronegative at all time-points by the 232 Tween 20 ELISA 
(Table 4.3).  
There was no difference in average optical density (OD) observed among any of the 
groups by the Oxoid assay (data not shown), but one M. hyopneumoniae isolate (97MP0001) 
induced significantly lower antibody levels compared to the three other M. hyopneumoniae 
challenge groups as measured by OD using 232 Tween 20 ELISA (Figures 4.1) and also the 
IDEXX ELISA (data not shown).  
 Table 4.1. Summary of the percentage of pneumonia, culture, and PCR results for pigs challenged with M. hyopneumoniae field 
isolates. 
     PCR results from NS, BS and BAL for each pig versus DPC 
    Culture results 7 14 21 28 42 56 70 96 
Group 
Necropsy 
(DPC) ID 
Pneumonia 
(%) NS BS NS NS NS NS BS BAL NS NS NS BS BAL NS BS BAL 
169 16.18   Mhp - + + + + +                 
28 172 22.31   Mhp - - + + + +          
153 23.79     + - + +   + - - + +     
70 157 0.00     + + + +   + - - - +     
163 0.12     + + + +   + - -   - - - Mhp 
97MP0001 96 170 1.21   Mhp + - + +     - + -     - + - 
158 10.62   Mhp - + + + + +          
28 162 31.52   Mhp + + + + + +          
159 0.00     + + + +   + + + - -     
70 160 0.01     + + + +   + + + + +     
161 0.82   Mhp + + + +   + + +   + + + Mhp 
95MP1501 96 164 1.73   Mhp + + + +     + + -     - + + 
755 12.98   Mhp + - + + + +          
28 762 2.32   Mhp + + + - + +          
70 773 0.00     + + - +   - - - + +     
752 0.48     + + - +   - - +   - - - Mhp  
00MP1301 96 767 0.15     - + + +     - - +     - - - 
768 27.56 Mhp, Mfl Mhp - + + + + +          
28 772 16.59 Mhp, Mfl Mhp + + + + + +          
757 6.94   Mhp - + + -   + - + + +     
70 759 21.79 Mfl Mhp + - + +   - - + + +     
751 0.83 Mfl   + - - -   - + -   - + + Mhp 
00MP1502 96 770 0.21 Mhp, Mfl   + + + +     + + +     + + + 
DPC = days-post-challenge; ID = pig identification number; NS = nasal swab; BS = bronchial swab; BAL = bronchial alveolar 
lavage fluid; Mhp = M. hyopneumoniae; Mfl = M.flocculare. 
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Table 4.2. Summary of pneumonia and culture results for pigs challenged with M. 
flocculare, M. hyorhinis and M. hyosynoviae. 
Group Necropsy (DPC) ID Pneumonia (%) Culture results 
    NS BS 
156 0.00 Mfl Mfl 
28 166 0.57  Mfl 
154 0.41 Mfl  
70 173 0.19 Mfl Mfl 
167 0.14  Mfl 
Mfl 7161B 96 168 0.12   
174 0.30 Mfl Mfl 
28 175 2.18 Mfl Mfl 
70 171 0.28 Mfl Mfl 
152 0.36   
Mfl 48LB 96 155 0.11  Mfl 
758 0.22 Mhr, Mhp Mhr, Mhp 
28 769 0.07 Mhr Mhr, Mhp 
754 0.58 Mhr Mhr, Mhp 
70 763 0.04 Mhr Mhr, Mhp 
756 0.32   
Mhr 96 774 0.31   
753 0.34 Mfl Mfl 
28 760 0.00 Mhs, Mfl Mfl 
761 0.17   
70 766 0.92  Mfl 
765 0.11  Mfl 
Mhs 96 771 0.05 Mfl  
DPC = days-post-challenge; Mfl = M. flocculare; Mhr = M. hyorhinis; Mhp = M. 
hyopneumoniae; Mhs = M. hyosynoviae; ID = pig identification number; NS = nasal 
swab; BS = bronchial swab.  
 
The Oxoid competitive-inhibition ELISA was previously manufactured as the DAKO M. 
hyopneumoniae ELISA. In order to compare the kits manufactured by Oxoid and DAKO, 
all sera were assayed by both ELISAs. No difference was observed in results produced by 
sera tested by either the DAKO, or the Oxoid ELISAs (data not shown). 
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Figure 4.1. 232 Tween 20 OD comparison of group means in M. hyopneumoniae-infected 
groups versus days-post-challenge. At each day-post-challenge, data points labeled with 
different lower case numbers letters are significantly different from each other, p < 0.05. 
Points above the horizontal line are considered positive. 
 
 
 
All pigs in the M. flocculare, M. hyorhinis and M. hyosynoviae groups seroconverted 
to the mycoplasma with which they were challenged. This was determined by observing 
rising OD values over time in the ELISAs performed for each species of mycoplasma 
(data not shown). In addition, pigs in the M. hyosynoviae group and the 00MP1502 M. 
hyopneumoniae group, seroconverted to M. flocculare. The Oxoid, IDEXX and 232 
Tween 20 ELISAs detected no antibodies from any of the pigs in groups experimentally 
challenged with M. flocculare, M. hyorhinis or M. hyosynoviae. Although M. 
hyopneumoniae was cultured from pigs in the M. hyorhinis group; these pigs did not 
develop detectable antibodies to M. hyopneumoniae.  
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Table 4.3. ELISA results from pigs challenged with M. hyopneumoniae field isolates.  
    Oxoid, IDEXX, 232 Tween 20 ELISA Results* 
  Days post challenge (DPC) 
Group ID 0 14 28 42 56 70 96 
97MP0001 153 -, -, - -, -, - +, -, - +, +, + +, +, + +, +, +  
 157 -, -, - +, -, - +, +, - +, +, - +, +/-, - +, -, -  
 163 -, -, - +, -, - +, +/-, +/- +, -, + +, +, + +, +, +/- +, +, +/- 
 169 -, -, - +, -, - +, -, -     
 170 -, -, - +, -, - +, +/-, - +, +, + +, -, + +, -, +/- +, -, +/- 
  172 -, -, - +, -, - +, -, -     
95MP1501 158 -, -, - +, -, - +, +, +         
 159 -, -, - +, -, - +, +/-, + +, +, + +, +, + +, +, +  
 160 -, -, - +, -, - +, -, - +, +, + +, +, + +, +, +  
 161 -, -, - +, -, - +, +/-, - +, +, + +, +, + +, +, + +, +, + 
 162 -, -, - +, -, - +, +/-, -     
  164 -, -, - +, -, - +, -, - +, +, + +, +, + +, +, + +, +, + 
00MP1301 752 -, -, - +, -,  - +, +/-, + +, +, + +, +, + +, +, + +, +, + 
 755 -, -, - +, -,  - +, -, -     
 762 -, -, - +, -, - +, +/-, -     
 767 -, -, - +, -, - +, +, + +, +, + +, +, + +, +, + +, +, + 
  773 -, -, - +, -, - +, +/-, +/- +, +, + +, +, + +, -, +   
00MP1502 751 -, -, - +, -, - +, +/-, + +, +, + +, +, + +, +, + +, +, + 
 757 -, -, - +, -, - +, +/-, - +, +, + +, +, + +, +, +  
 759 -, -, - +/-, -, - +, -, +/- +, +, + +, +, + +, +, +  
 768 -, -, - +, -, - +, +, +     
 770 -, -, - +, -, - +, +, + +, +, + +, +, + +, +, + +, +, + 
  772 -, -, - +, -, - +, +/-, +/-         
* Samples are categorized as positive (+), negative (-), or suspect (+/-) by the Tween 20 
and IDEXX ELISAs and + or – by the Oxoid ELISA. ID = pig identification number. 
 
97MP0001 Tween 20 ELISA. Serum from all pigs in each of the four M. 
hyopneumoniae challenge groups were tested using the 97MP0001 Tween 20 ELISA 
plates. The results are summarized as group averages for each time point in Figure 4.2. 
The only time-point when any groups were significantly different from each other was 42 
DPC. 
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Figure 4.2. 97MP0001 Tween 20 OD comparison of group means in M. hyopneumoniae-
infected groups versus days-post-challenge. At 42 days-post-challenge, data points 
labeled with different lower case numbers letters are significantly different from each 
other, p < 0.05. 
 
PCR. Results from the M. hyopneumoniae PCR assays on nasal and bronchial swabs 
and BALF are summarized in Table 4.1. More positive results were obtained at 28 DPC 
than at either 70, or 96 DPC. Samples from BALF and bronchial swabs were each 
positive in 21 of 23 samples while samples collected from nasal swabs were positive in 
100 of 145 samples. The number of positive results for each sample-type peaked at 28 
DPC. 
Western blot. Sera from pigs in each of the M. hyopneumoniae challenge groups were 
evaluated in a western blot assay using Tween 20-extracted antigen from isolate 
97MP0001 (Figure 4.3). Except for sera from pig 153, the intensity of bands from pigs 
challenged with isolate 97MP0001 were less than was observed from pigs challenged 
with the other three M. hyopneumoniae isolates. Pig 153 was the only pig in the 
97MP0001 challenge-group that was positive by all three ELISAs at the 40, 56 and 70 
DPC time-points. 
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Figure 4.3. Western blot results detecting proteins from antigen prepared from M. 
hyopneumoniae isolate 97MP0001.  Included are sera from pigs in each of the four M. 
hyopneumoniae challenge-groups at 0 and 56 days-post-challenge (DPC). Numbers along 
the left side of the figure indicate molecular weight markers. ID = Pig identification 
number. 
Discussion 
Enzyme-linked immunosorbent assays are the most commonly used tool to monitor 
herds and screen replacement animals for exposure to M. hyopneumoniae. Here the 
sensitivities and specificities of three M. hyopneumoniae ELISA assays used in the 
United States were compared. Groups of pigs were experimentally infected with four 
species of mycoplasmas commonly found in swine. In addition, multiple isolates of M. 
hyopneumoniae and M. flocculare were included to further examine the effect of strain 
variation within species. The current study differs from previous studies directly 
comparing the sensitivity and specificity of the Tween 20, IDEXX and Oxoid (Dako) M. 
hyopneumoniae-specific ELISAs which used sera collected from pigs challenged with M. 
hyopneumoniae strain 232 and/or field samples (1, 7) and had no groups experimentally 
challenged with other Mycoplasma species. Strain 232 is used to produce the antigen for 
the Tween 20 ELISA and was derived from an in vivo pig passage of strain 11, which is 
one of the original strains of M. hyopneumoniae (23). Testing sera collected from pigs 
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challenged with strain 232 may not be representative of current conditions in the field. A 
number of other species of mycoplasmas and acholeplasmas have also been isolated from 
pigs (22), but their prevalence is unclear. The effect antibodies to these organisms have 
on the specificity of M. hyopneumoniae ELISAs was not examined, but may warrant 
further study. 
In this study the Oxoid ELISA was the most sensitive assay detecting antibodies in 
pigs at 14 DPC, the earliest time point that sera was collected after infection. Neither the 
232 Tween 20, nor the IDEXX ELISA detected antibodies until the 28 DPC time-point. 
The 232 Tween 20 and IDEXX ELISAs performed similarly to each other in this study 
overall, but differed 24% of the time on individual results from 28-96 DPC (Table 4.3). 
Within these differences there was an equal detection of positive, suspect, or negative by 
each ELISA, rather than one assay being consistently more positive than the other. 
Erlandson, et al. suggested that the positive-cut off in the 232 Tween 20 ELISA was set 
more conservatively than either the IDEXX or DAKO (now Oxoid) assays (7). Although 
in the current study lowering the cut-off of the 232 Tween 20 ELISA did not substantially 
improve the agreement between the two indirect ELISAs (data not shown). Higher 
agreement between the two indirect assays might be expected because the antigens used 
in the IDEXX and 232 Tween 20 ELISAs are produced by the same technique with the 
primary difference between the tests being the isolate of M. hyopneumoniae used for 
antigen production.  
Unlike the immune response to many pathogens, antibodies to M. hyopneumoniae can 
take weeks to months to reach detectable levels after infection. Under field conditions 
challenge dose may further impact the rate of seroconversion; therefore, multiple time-
points for serology may be necessary to identify positive pigs. Combining the Oxoid 
ELISA with either the 232 Tween 20 or IDEXX ELISA increases sensitivity as has been 
previously reported (7).  
Few reports of false-positives in any of these ELISAs exist (4). In the current study, 
the M. flocculare, M. hyorhinis and M. hyosynoviae groups each had pigs with detectable 
antibodies to the species of mycoplasmas with which they were challenged. The M. 
hyorhinis challenge group was also cultured positively for M. hyopneumoniae, but these 
pigs did not develop detectable antibodies to M. hyopneumoniae by any of the ELISAs 
(data not shown). The M. hyosynoviae group and one were also culture-positive for M. 
flocculare. These groups did seroconvert to M. flocculare (data not shown). It was not 
determined whether these additional infections came from the source-herd, or were due to 
cross-contamination between challenge groups during the study.  
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A previous study compared the DAKO ELISA (now manufactured as the Oxoid 
ELISA) to the IDEXX ELISA and identified field sera that were positive by the DAKO 
ELISA, but negative by the IDEXX ELISA and vice versa (1). The discrepancies in the 
results between these tests were further assessed using an immunoblot assay (2) and it 
was suggested that a sample found positive by either test was truly positive, although this 
requires further validation as the true infection-status of the animals in this study was 
unknown. 
When the M. hyopneumoniae-specific ELISAs were compared for their ability to 
detect antibodies to different field isolates of M. hyopneumoniae, variation in the 232 
Tween 20 and IDEXX ELISAs was observed. Specifically, pigs challenged with M. 
hyopneumoniae isolate 97MP0001 had significantly lower ODs than was observed in any 
of the other M. hyopneumoniae groups. One explanation for the lower ODs observed in 
the 97MP0001 group is that pigs challenged with the 97MP0001 isolate had a less severe 
challenge; however, the percentage of macroscopic pneumonia indicates otherwise. At 28 
DPC, the time-point normally associated with the most severe pneumonia after 
experimental challenge, pigs in the 00MP1301 group appeared to have the least amount 
of pneumonia. In addition, M. hyopneumoniae was detected in pigs from all four M. 
hyopneumoniae challenge groups until the end of the study at 96 DPC by PCR indicating 
that isolate 97MP0001 was not cleared from the pigs at a different rate than the other 
three M. hyopneumoniae isolates. In this study, each time point was represented by only 
two pigs which does not allow for statistical comparisons to be made. Another possible 
explanation for the lower OD levels is that antibodies produced in the pigs challenged 
with isolate 97MP0001 less effectively bound the antigen used in the 232 Tween 20 and 
IDEXX ELISAs. To test this, sera from pigs in all of the M. hyopneumoniae groups were 
assayed using a Tween 20 ELISA with antigen produced from isolate 97MP0001. Similar 
to the results observed with the IDEXX ELISA and the 232 Tween 20 ELISA, pigs 
challenged with isolate 97MP0001 had the lowest OD values in the 97MP0001 Tween 20 
ELISA. However differences between the three indirect ELISAs did exist as the OD 
values observed for the four challenge groups in each of the ELISAs was not equivalent 
suggesting that at least some of the variation can be attributed to the antigen.  
A final explanation for the differences in results observed in sera from pigs in the 
97MP0001 group may be due to lower levels of antibodies induced by the isolate. A 
western blot using sera from each of the M. hyopneumoniae groups before challenge 
(0DPC) and at the time of peak ODs (56 DPC) was performed using 97MP0001 Tween 
20 antigen. Again even though, antibodies to homologous antigen might have been 
expected to produce the strongest bands, this was not observed. Except for pig 156, it 
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appears that fewer antibodies were produced by pigs challenged with isolate 97MP0001 
than by pigs challenged with the other three M. hyopneumoniae isolates. Pigs in the M. 
hyopneumoniae group 00MP1502 were also infected with M. flocculare. It is unclear if 
antibodies to M. flocculare are being detected in the western blot, or what affect they may 
have on these results. Field isolate 97MP0001 could potentially possess a mechanism for 
skewing the immune response away from the humoral response.  
In the present study no differences were observed in the ability of the Oxoid ELISA 
to detect antibodies against any of the field isolates at any time-point, unlike what was 
observed in the Tween 20 and IDEXX ELISAs. The Tween 20 and IDEXX ELISAs are 
indirect assays using antigen prepared from Tween 20 extracts of whole-cell organisms. 
In these two assays, rising OD values directly correlate to increasing levels of antibodies. 
The Oxoid ELISA is a competitive-inhibition assay measuring antibodies to a single 
protein. In this assay, OD levels do not correlate in a linear manner to antibody levels. 
Distinguishing between samples with different levels of antibodies using the Oxoid 
ELISA is more difficult compared to the indirect ELISAs. This likely explains the 
differences observed between the two types of ELISAs. 
Bereiter, et al. found that pigs with high antibody levels against M. flocculare can 
potentially cause false-positive results in the 232 Tween 20 ELISA (4). In the current 
study sera from pigs challenged with M. flocculare had rising OD values in the M. 
flocculare Tween 20 ELISA over time and appeared to seroconvert. No evidence of 
cross-reactivity was attributed to the M. flocculare antibodies in the current study. 
However, peak M. flocculare OD values in these samples were 3-5 times lower than was 
observed by Bereiter, et al. As a result, the ability of high levels of M. flocculare 
antibodies to cross-react in the 232 Tween 20 ELISA remains unresolved. Pigs in the M. 
hyopneumoniae group, 00MP1502, and the M. hyosynoviae group were also infected with 
M. flocculare; however, these ODs were also lower than was observed by Bereiter, et al. 
The M. hyopneumoniae PCR results from nasal and bronchial swabs and BALF 
showed that early in infection all of these samples effectively produced positive results. 
At later necropsy time-points, BALF was more likely to have positive results followed by 
bronchial swabs, and then nasal swabs as has been previously shown (10). In addition, 
culture of M. hyopneumoniae was more likely to occur from pigs necropsied at 28 DPC 
than those necropsied at either 70 or 96 DPC and bronchial swabs were much more often 
successful than nasal swabs. In this study the swabs and BALF for PCR and culture were 
collected from pigs experimentally challenged at an infectious dose much higher than 
would occur in the field, but still demonstrate that the use of nasal swabs late in infection 
 68 
is more likely to produce false-negative results than either BALF or bronchial swabs for 
both PCR and culture.  
The results of the current study suggest that seroconversion to field isolates of M. 
hyopneumoniae in pigs is not uniform. More studies need to be performed with the 
indirect ELISAs to determine if the M. hyopneumoniae isolates currently used for antigen 
production should be updated. Differences in virulence among isolates of M. 
hyopneumoniae did not appear to correlate to the level of antibodies detected by either 
ELISA or western blot, although this should be further investigated in a study using more 
pigs. It is currently unknown if antibodies to any proteins occur early in infection versus 
late, or what the effect of a low versus high infectious dose has on the detection rate of 
ELISAs. Therefore, M. hyopneumoniae serology is best used on a herd basis rather than 
on an individual pig basis, and screening of individual replacement animals by ELISA 
requires careful interpretation.  
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CHAPTER 5. EFFICACY OF A MYCOPLASMA HYOPNEUMONIAE 
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VACCINES 
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Summary 
Objective: The efficacy of a Mycoplasma hyopneumoniae (M hyo) bacterin was evaluated 
against two contemporary field isolates of M hyo. 
Methods: Two challenge studies were performed in which pigs received two doses of saline 
(nonvaccinated groups), or a M hyo bacterin (vaccinated groups), followed three weeks later 
by intratracheal inoculation with one of two M hyo field isolates. Necropsies were performed 
28 or 30 days-post-challenge (DPC). Vaccine efficacy was determined by evaluating 
macroscopic lung lesions, DNA levels of M hyo in bronchial alveolar lavage fluids (BALF), 
M hyo-specific immunoglobulin (Ig)A and IgG antibodies, and serum antibodies measured 
by the Tween 20 and DAKO ELISAs. 
Results: The percentage of macroscopic lung lesions and concentration of M hyo DNA in 
BALF samples following challenge with either isolate were significantly less in vaccinated 
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compared to nonvaccinated pigs. M hyo-specific mucosal IgA and IgG antibody levels in 
BALF were significantly higher in the vaccinated pigs compared to the nonvaccinated pigs.  
Implications: Under the conditions of this study, pigs vaccinated with a M hyo bacterin prior 
to challenge with virulent field isolates of M hyo had fewer M hyo organisms and less 
pneumonia compared to nonvaccinated pigs. Vaccination is an effective tool to reduce 
pneumonia induced by M hyo, although more studies need to be performed to determine 
protection against a wide range of field isolates. 
 
Introduction 
Mycoplasma hyopneumoniae (M hyo) is the causative agent of enzootic pneumonia, but 
more importantly, it is a primary component of the porcine respiratory disease complex. The 
impact of disease caused by M hyo leads to significant economic losses in the swine industry 
today. M hyo is an extracellular pathogen that resides primarily on the ciliated respiratory 
epithelium of the lower respiratory tract where it induces a delayed humoral immune 
response in the pig. Currently available commercial bacterins are unable to prevent M hyo 
colonization in the lungs, but have been shown to significantly reduce the severity of 
pneumonia in vaccinated pigs.1,2 Most experimental studies evaluating the efficacy of M hyo 
bacterins have relied on challenge models with older reference strains of M hyo. Many of 
these studies have used a model developed at Iowa State University that consists of an 
intratracheal inoculation of a diluted lung homogenate containing pig-passaged strain 2321,2, 
that derives from strain 11 which was cultured in the 1960’s.3  Recently, a range of virulence 
among M hyo isolates has been demonstrated.4,5,6 In addition genotypic and phenotypic 
variation among isolates has been shown to exist,  although specific implications of these 
differences have not yet been identified.7,8,9,10,11,12  It is currently unknown if differences in 
virulence factors or other putative immunogens affect the ability of current vaccines to 
protect against different field isolates of M hyo. As a result, there is a need to measure the 
efficacy of M hyo vaccines against a variety of field isolates. 
In the study reported here, pigs were assigned to one of two treatment groups that received 
either a M hyo bacterin or saline. An equal number of pigs from each treatment group were 
then challenged with one of two different contemporary M hyo field isolates. The M hyo 
isolates used in this study, 95MP1509 and 00MP1301,6 are genetically distinct from each 
other and from strain 232.12 The parameters used to measure efficacy included macroscopic 
lung lesions, M hyo level in the lungs as assessed by a real-time polymerase chain reaction 
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(PCR), M hyo-specific Immunoglobulin (Ig)G and IgA antibodies in bronchial alveolar 
lavage fluids (BALF) measured by enzyme-linked immunosorbent assays (ELISA), and M 
hyo-specific serum antibodies were assessed by Tween 20 and DAKO ELISAs. 
Materials and Methods 
Study animals 
Ninety-three weaned and castrated male crossbred pigs, 9 to 14 days of age from a 
commercial farrowing unit were transported to the Iowa State University Animal Research 
Facilities in Ames, Iowa.  The source herd had no history of vaccination against M hyo and 
was serologically free of M hyo and porcine reproductive and respiratory virus. No clinical 
signs of swine influenza virus were present in the pigs at the time of arrival. All animal 
procedures and care were conducted under the supervision and regulations of the Iowa State 
University Institutional Animal Care and Use Committee. 
Experimental design 
Eighty-four pigs were distributed into two separately housed challenge groups. Each group 
was randomly assigned to 7 pens of 6 pigs according to a generalized block design. Within 
each pen, three pigs were vaccinated with the M hyo bacterin and three pigs received saline 
(nonvaccinates). Two groups of three procedural negative control pigs were separately 
housed in a different facility and received no treatment or challenge. Food and water were 
supplied ad libitum throughout the study. At approximately 3 and 5 weeks of age, pigs were 
injected intramuscularly (IM) in the right and left neck, respectively, with 2 mL of an M hyo 
bacterin (RespiSure®; Pfizer Animal Health, New York, New York) or 2 mL of 0.9% saline 
as per treatment assignment and designated as vaccinated and nonvaccinated pigs, 
respectively. At approximately 8 weeks of age, each challenge group of pigs was inoculated 
intratracheally with a M hyo broth culture containing between 107 and 108 color changing 
units (CCU) per mL of either field isolate 95MP1509 or 00MP1301 on 3 consecutive days 
designated 0, 1 and 2 days post challenge (DPC) as previously described.1 Both 95MP1509 
and 00MP1301 were isolated from pigs submitted to the Iowa State University Veterinary 
Diagnostic Laboratory in 1995 and 2000, respectively. Due to the large number of pigs in the 
study, pigs challenged with isolate 95MP1509 were necropsied at 28 days DPC, and pigs 
challenged with 00MP1301were necropsied at 30 DPC. The investigators were blinded to 
vaccination status of the pigs until all the results from all study parameters were collected. 
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Serum antibody tests  
Blood for serology was collected prior to each vaccination, prior to challenge, and at 
necropsy. All serum samples were frozen at -20°C until the end of the study and then batch-
tested by the Tween 20 ELISA13 and the DAKO M hyo blocking ELISA (DAKO 
Corporation, Carpenteria, California). For the Tween 20 ELISA, all samples were tested in 
duplicate and the average optical density (OD) of the two was used. The positive control was 
normalized to an OD of 0.4, and the samples were then adjusted accordingly. Optical 
densities ≥ 0.24 were defined as positive. Negative results were defined as OD < 0.2, and an 
OD < 0.24, ≥ 0.2 was defined as suspect. For the DAKO ELISA, a sample was defined as 
positive if the percent inhibition of the sample was ≤ 50% of the buffer control. Samples with 
an OD > 50% of the buffer control were defined as negative.  
Necropsy 
All animals, including the procedural negative-control pigs, were euthanized using an 
AVMA-approved euthanasia solution (Fatal-Plus; Vortech Pharmaceuticals, Ltd, Dearborn, 
Michigan) followed by exsanguination.  
Lung lesions consistent with M hyo pneumonia were sketched on a standard diagram and 
assessed for the proportion of lung surface with lesions using a Zeiss SEM-IPS image 
analyzing system (Carl Zeiss, Inc, Thornwood, New York) as previously described.1  
Bronchial swabs were cultured for respiratory pathogens of swine including Bordetella 
bronchiseptica, Pasteurella multocida, Actinobacillus spp., and Haemophilus spp. Samples 
were inoculated onto blood agar plates and streaked with a Staphylococcus epidermidis nurse 
colony for support of A. pleuropneumoniae and Haemophilius spp.   
In addition, bronchial swabs were inoculated into BHI-TS mycoplasma medium14 for M. 
hyorhinis isolation and Friis medium15 for isolation of M hyo. Species identification of 
mycoplasma cultures was confirmed using a multiplex PCR for M hyo, Mycoplasma 
flocculare and Mycoplasma hyorhinis as previously described.16  
BALF was collected using 25 mL of sterile phosphate buffered saline (PBS) as previously 
described.17 BALF samples were assayed by ELISA for local IgA and IgG antibodies to M 
hyo18 and for M hyo DNA by real-time PCR. For the real-time PCR, a 1 mL aliquot of BALF 
from each pig was centrifuged at 16,000g for 10 minutes. The resulting pellet was 
resuspended in 200 µL of PBS. DNA was isolated using the QIAamp DNA mini kit (Qiagen, 
Valencia, California). DNA was also isolated from M hyo strain 232 by phenol-chloroform 
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extraction19 for use in generating a standard curve for semi-quantitative analysis. The real-
time PCR (REP assay), which targets the repeated element MHYP1-03-950 (accession no. 
AF004388), was performed with minor modifications as previously described.20 The 
concentration used for the probe was 250 nM. An internal positive control was added to 
control potential inhibition caused by the DNA sample (Applied Biosystems, Foster City, 
California). The 10X exogenous internal positive control mix and 50X exogenous internal 
positive-control DNA were diluted two-fold further than recommended by the manufacturer 
to prevent interference within the assay. All PCR reactions were performed in duplicate on a 
Rotor-Gene RG-3000 (Corbett Research, San Francisco, California). Results were quantified 
by comparison to a standard curve generated for each run using Rotor-Gene 5 software 
(Corbett Research) and expressed as ng per µL DNA, duplicate samples were then averaged 
together.  
Data analysis 
The two challenge groups were treated as separate studies for the purposes of randomization 
and statistical analysis. In all analyses, the individual pig was the experimental unit. 
The arcsine square root transformation was applied to the total percentage lung involvement 
prior to analysis, and the transformed percent lung scores were analyzed with a general linear 
mixed model with fixed term treatment and random term block.  
 For each antibody test procedure, OD values were back-transformed to obtain geometric 
mean titers prior to analysis. Transformed serum antibody values were analyzed with a 
general linear repeated measures mixed model with fixed effects: treatment, time point, and 
treatment by time-point interaction, and random effects: block and animal within block by 
treatment. The positive-negative status for both Tween 20 and DAKO ELISAs were analyzed 
with a generalized linear repeated measures mixed model (GLIMMIX) with fixed effects: 
treatment, time point, and treatment by time-point interaction, and random effects: block and 
animal within block by treatment. Suspect results as described above for the Tween 20 assay 
were considered negative for the analysis. M hyo IgA and IgG mucosal antibody titers and 
real-time PCR concentrations from BALF were analyzed with a generalized linear mixed 
model with fixed effect treatment and random effects terms block. If the model (via the 
GLIMMIX macro) did not converge when analyzing positive-negative status, then Fisher’s 
exact test was used to analyze that variable. All analyses were performed using SAS/STAT 
guide version 8 (SAS institute, Inc, Cary, North Carolina). The 5% level of significance (P < 
.05) was used to assess statistical differences. 
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Results 
Death of animals during the study 
One pig in the nonvaccinated group (95MP1509 challenge) and two pigs in the vaccinated 
group (00MP1301 challenge) died of causes not related to the study. 
Serology 
The OD values for all pigs were classified as negative for M hyo-specific antibodies in the 
Tween 20 and DAKO ELISAs at beginning of the study and prior to vaccination. The 
nonvaccinated pigs remained negative for M hyo antibodies prior to challenge and the 
procedural negative control pigs remained serologically negative at all time points 
throughout the trial (data not shown). The percentage of antibody positive pigs as measured 
by the Tween 20 and DAKO assays are summarized in Table 5.1.  
The OD levels measured by the Tween 20 assay were significantly higher (P < .001) in 
vaccinated pigs than in nonvaccinated pigs from both the 95MP1501 and 00MP1301 
challenge groups prior to challenge and at necropsy (Table 5.2).  
Macroscopic lung lesions 
Analysis of the percentage of macroscopic lung lesions is summarized in Table 5.3. The 
mean percent lung involvement in vaccinated pigs was significantly lower than observed in 
nonvaccinated pigs (P <. 001) in both challenge studies [95MP1509 (5.1% compared to 
19.3%) and 00MP1301 (1.2% compared to 7.4%)].  
The distribution of lung lesions by severity is summarized in Table 5.4. The macroscopic 
lung lesion scores for the procedural negative control pigs averaged 0.36% for the 00MP1301 
challenge study and 1.1% for the 95MP1509 study. 
M hyo real-time PCR 
Detection of M hyo DNA in BALF samples taken at necropsy is summarized in Table 5.5. 
Following challenge with either isolate, the level of M hyo DNA detected in vaccinated pigs 
was significantly lower (P < .001) than the level detected in the nonvaccinated pigs. 
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Table 5.1. Frequency of pigs positive for M hyo Tween 20 and DAKO serum antibody titers 
in pigs vaccinated twice with an M hyo bacterin, or saline, then challenged with M hyo, and 
necropsied 28 DPC (95MP1509 challenge) or 30DPC (00MP1301 challenge). 
   Pigs positive (%) 
Challenge 
isolate 
Treatment Test 
-33DPC/ 
Vacc 1 
-19DPC/ 
Vacc 2 
-1DPC* 28/30DPC† 
Tween 20 
0 0 0 60 Saline 
DAKO 
0 0 0 100 
Tween 20 
0 0 76 100 
95MP1509 
M hyo 
bacterin DAKO 
0 5 100 100 
Tween 20 
0 0 0 67 
Saline 
DAKO 
0 0 0 100 
Tween 20 
0 0 74 100 
00MP1301 
M hyo 
bacterin DAKO 
0 5 100 100 
*For each challenge isolate, the percentage of MHYO vaccinates positive by Tween 20 and 
DAKO test was higher (P < .001) than saline controls.  
†For each challenge isolate, the percentage of MHYO vaccinates positive by Tween 20 assay 
was higher (P < .01) than saline controls. 
DPC=days post challenge, Vacc 1=day of first vaccination, Vacc 2=day of second 
vaccination. 
 
For the Tween 20 ELISA, the positive control was normalized to an OD of 0.4, and the 
samples were then adjusted accordingly. Optical densities ≥ 0.24 were defined as positive. 
Negative results were defined as OD < 0.2, and an OD < 0.24, ≥ 0.2 was defined as suspect. 
Suspect titers were treated as negative for analysis. For the DAKO ELISA, a sample was 
defined as positive if the percent inhibition of the sample was ≤ 50% of the buffer control. 
Samples with an OD > 50% of the buffer control were defined as negative. The positive-
negative status for both Tween 20 and DAKO ELISAs was analyzed with a generalized 
linear repeated measures mixed model (GLIMMIX) with fixed effects: treatment, time point, 
and treatment by time point interaction, and random effects: block and animal within block 
by treatment. If the model (via the GLIMMIX macro) did not converge when analyzing 
positive-negative status, then Fisher’s exact test was used to analyze that variable at each 
time point. 
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Table 5.2. M hyo Tween 20 serum antibody titers in pigs vaccinated twice with an M hyo 
bacterin, or saline, then challenged with M hyo, and necropsied 28 DPC (95MP1509 
challenge) or 30DPC (00MP1301 challenge). 
Tween 20 serum antibody titers (Mean OD ± SE)* 
Challenge 
isolate 
Treatment 
 
No. of 
pigs 
 -33DPC/Vacc 
1 
-19DPC/Vacc 
2 
-1DPC 28/30DPC 
Saline 
20 
0.022 + 0.000 0.016 + 0.000 
0.031 + 
0.000 
0.273 + 0.004 
95MP1509 
M hyo 
bacterin 
21 
0.018 + 0.000 0.021 + 0.000 
0.323 + 
0.008 
0.962 + 0.017 
Saline 
21 
0.025 + 0.000 0.017 + 0.000 
0.026 + 
0.000 
0.292 + 0.006 
00MP1301 
M hyo 
bacterin 
19 
0.023 + 0.000 0.014 + 0.009 
0.340 + 
0.009 
0.935 + 0.028 
* Back-transformed geometric mean titer ± standard error. 
† M hyo bacterin titers were significantly higher (P < .001) than the saline placebo in both 
challenge groups at the -1DPC and 28/30DPC time points. DPC=days post challenge, Vacc 
1=day of first vaccination, Vacc 2=day of second vaccination. Serum antibody titers were log 
transformed and analyzed with a general linear repeated measures mixed model with fixed 
effects treatment, time point, and treatment by time-point interaction, and random effects 
block and animal-within-block by treatment. The individual pig was the experimental unit. 
 
IgA and IgG antibodies  
Significantly higher (P < .001) OD levels corresponding to M hyo-specific mucosal IgA and 
IgG antibodies were detected in vaccinated pigs compared to nonvaccinated pigs in both 
challenge groups (Table 5.6). The IgA and IgG optical density (OD) values for all procedural 
negative control pigs were low (OD < 0.07 for all samples; data not shown).  
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Table 5.3. Parametric analysis of M hyo percent lung lesions in pigs vaccinated twice with an 
M hyo bacterin, or saline, then challenged with M hyo, and necropsied 28 DPC (95MP1509 
challenge) or 30DPC (00MP1301 challenge). 
Challenge 
isolate 
Treatment No. of pigs 
LS mean % ± 
SE* 
Range (%) 
95MP1509 Saline 20 19.3 + 3.1 3 - 47 
 M hyo bacterin 21 5.1 + 1.7† 0 - 43 
00MP1301 Saline 21 7.4 + 1.4 1- 28 
 M hyo bacterin 19 1.2 + 0.6‡ 0 - 19 
 
* Back-transformed least squares mean + standard error. 
† M hyo vaccinates lower (P< .001) than saline controls. 
‡ M hyo vaccinates lower (P< .001) than saline controls. 
 
The arcsine square root transformation was applied to the total percentage lung involvement 
prior to analysis. The transformed percent lung scores were analyzed with a general linear 
mixed model with fixed term treatment and random term block 
 
Bacterial isolation from bronchial swabs  
No primary swine bacterial pathogens were isolated from any pigs at necropsy. 
Streptococcus suis was isolated from nine and three pigs in the 95MP1509 and 00MP1301 
challenge groups, respectively, but no clinical disease associated with this bacterium was 
observed. Culture for the detection of viable M hyo was positive in 19 of 20 nonvaccinated 
pigs and 18 of 21 vaccinated pigs challenged with 95MP1509 and for 20 of 21 non-
vaccinated and 16 of 19 vaccinated pigs challenged with 00MP1301. There were no 
differences in the isolation rate for any bacterial species between any of the groups. All 
procedural negative control pigs from each challenge study were negative for isolation of all 
bacterial species except for one pig from which M hyo was cultured.  
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Table 5.4. Frequency distribution of percentage lung lesions at necropsy in pigs vaccinated 
twice with an M hyo bacterin, or saline, then challenged with M hyo, and necropsied 28 DPC 
(95MP1509 challenge) or 30DPC (00MP1301 challenge). 
Frequency Distribution of Lung Lesion Score 
(percentage of pigs per range) Challenge 
Isolate 
Treatment 
No 
of 
Pigs < 2% 2 < 5% 
5 < 
10% 
10 < 
20% 
20 < 
30% 
> 30% 
Saline 20 0% 5% 20% 30% 20% 25% 
95MP1509 MHYO 
bacterin 
21 48% 24% 5% 5% 14% 5% 
Saline 21 14% 29% 19% 29% 10% 0% 
00MP1301 MHYO 
bacterin 
19 68% 21% 0% 11% 0% 0% 
 
 
Table 5.5. M hyo real-time polymerase chain reaction levels in bronchial alveolar lavage 
fluids (BALF) at necropsy in pigs vaccinated twice with an M hyo bacterin, or saline, then 
challenged with M hyo, and necropsied 28 DPC (95MP1509 challenge) or 30DPC 
(00MP1301 challenge). 
M hyo DNA (ng/µL) Challenge 
isolate 
Treatment 
GMT + SE* Range 
95MP1509 Saline 2.415 + 0.622 0.49-11.29 
 M hyo bacterin 0.378 + 0.095† 0.02-2.62 
00MP1301 Saline 1.188+ 0.502 0.01-6.14 
 M hyo bacterin 0.110 + 0.049‡ 0.00-2.32 
*Back-transformed geometric mean titer + standard error. 
† M hyo vaccinates lower (P<0.001) than nonvaccinates. 
‡ M hyo vaccinates lower (P<0.001) than nonvaccinates. 
A log transformation was applied to titer values and titers were analyzed with a generalized 
linear mixed model with fixed effect treatment and random effects block. 
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Table 5.6. M hyo-specific IgA and IgG antibodies in bronchial alveolar lavage fluids (BALF) 
at necropsy in pigs vaccinated twice with an M hyo bacterin, or saline, then challenged with 
M hyo, and necropsied 28 DPC (95MP1509 challenge) or 30DPC (00MP1301 challenge). 
BALF M hyo antibodies (OD) 
Challenge isolate Treatment IgA† 
(GMT OD + SE*) 
IgG† 
(GMT OD + SE*) 
Saline 0.236 + 0.017 0.377 + 0.025 
95MP1509 
M hyo bacterin 0.486 + 0.035 0.970 + 0.062 
Saline 0.257 + 0.018 0.399 + 0.041 
00MP1301 
M hyo bacterin 0.458 + 0.020 0.932 + 0.041 
*Back-transformed geometric mean titer optical density (OD) ± standard error. 
†For both challenge studies, immunoglobulin (Ig)A and IgG OD titers in the M hyo 
vaccinates were higher (P<0.001) than saline controls. 
For each antibody isotype a log transformation was applied to OD titer values and analyzed 
with a generalized linear mixed model with fixed effect treatment and random effects block. 
Discussion 
This study investigated the efficacy of a M hyo bacterin against two contemporary M hyo 
isolates. These isolates had previously been shown to produce more macroscopic lung lesions 
than the prototypic challenge strain 232.6 Following challenge with either strain of M hyo, 
the severity of macroscopic lung lesions in the vaccinated pigs was significantly less than in 
the nonvaccinated pigs. In both challenge studies, vaccinates had significantly lower 
concentrations of M hyo DNA in BALF, as detected by real time-PCR. In addition, higher 
OD values relating to mucosal M hyo-specific IgA and IgG antibodies were present in BALF 
samples collected at necropsy from vaccinated compared to nonvaccinated pigs. No 
differences were observed in the percentage of pigs from which M hyo was isolated between 
vaccinates and nonvaccinates in the two challenge groups at necropsy. One of the pigs in the 
procedural negative controls cultured positive for M hyo. This was likely due to post-harvest 
contamination as the procedural control pigs were housed in a different facility than the 
challenged pigs and did not exhibit any clinical signs of pneumonia at necropsy. A low 
percentage of macroscopic lesions was observed in the lungs of the some of the procedural 
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control pigs, but this is consistent with background levels normally observed in our challenge 
models using conventional pigs. 
Serology is a common tool used for monitoring herd status of M hyo as well as determining 
vaccination compliance. It has been suggested using field sera that the immune response in 
pigs infected with M hyo is not uniform and that these differences may impact the sensitivity 
of M hyo-specific ELISAs.21 Therefore two different M hyo ELISAs were used to evaluate 
M hyo serum antibodies in this study. Both the Tween 20 and DAKO ELISAs detected M 
hyo-specific serum antibodies in vaccinated pigs from each challenge group after two 
vaccinations. The antibody levels in the vaccinated pigs increased following challenge 
indicative of an anamnestic response. Direct comparisons of ODs between the vaccinates and 
nonvaccinates were made using Tween 20 results as OD values in this assay correlate to M 
hyo-specific antibody levels. In contrast, the DAKO ELISA is a competitive inhibition assay 
and OD values do not directly correlate to antibody levels. In the current study, the DAKO 
ELISA was more sensitive at earlier time-points after challenge with either field isolate 
similar to what has been previously shown using sera from pigs experimentally challenged 
with M hyo strain 232.22  
Anecdotal reports from the field suggest that variation in M hyo isolates may play a role in 
mycoplasmal vaccine failure. Results from the studies presented here indicate that the M hyo 
vaccine provided protection against mycoplasmal pneumonia in pigs challenged with more 
recent M hyo field isolates. This challenge model is a more severe exposure than would 
occur in a natural field infection. Because challenge with culture may be less reproducible 
than with lung inoculum, pigs were inoculated on three consecutive days as has been 
previously described.23 In addition, both vaccinated and non-vaccinated pigs were co-
mingled. Therefore, any effect of population immunity on shedding of M hyo was lost. 
Although these studies were analyzed separately and therefore were not directly compared, 
the 95MP1501 challenge resulted in more pigs in the saline treatment group with higher 
gross lesion scores (> 10%) than was observed in the saline treatment group in the 
00MP1301 challenge.  In addition, 19% of vaccinated pigs in the 95MP1501 group had 
pneumonia affecting > 20% of the lung, while most of the vaccinated pigs (89%) in the 
00MP1301 group had lung lesions affecting < 5% of the lung. The severity of the challenge 
model may partially explain the high lung-lesion scores observed in pigs challenged with 
isolate 95MP1509. Alternatively this may demonstrate a lack of protection in these pigs 
against this isolate.  
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Currently, the importance of genetic variation on cross protection between M hyo isolates is 
not known. Since the virulence factors for M hyo have not been identified, the protective 
antigens required in a vaccine remain undefined. Neither of the field isolates used in this 
study has been used in commercial vaccine production. In addition, it is not known how 
genetically similar these two field isolates are to strains of M hyo currently used in M hyo 
bacterins. No M hyo genes, or gene products have been correlated to protection against 
disease caused by M hyo; therefore, no suitable targets for sequencing exist for comparison 
of field isolates in relation to virulence or protection from disease. 
This report measured vaccine efficacy following experimental challenge with two recent 
virulent M hyo field isolates. Further studies need to be performed to evaluate genetic and 
antigenic differences in M hyo isolates to better understand their implications in disease and 
vaccine efficacy.  
Implications 
Under the conditions of these studies, fewer M hyo organisms and less macroscopic lesions 
of pneumonia are observed when pigs are vaccinated with an M hyo bacterin prior to 
challenge with two contemporary virulent field isolates of M hyo. 
Pigs vaccinated with a M hyo bacterin develop increased serum antibodies, as detected by 
Tween 20 and DAKO ELISAs, and increased local M hyo-specific IgG and IgA antibodies in 
BALF at necropsy, compared to nonvaccinated pigs.  
Vaccination is an effective tool to reduce macroscopic lesions induced by M hyo, although 
more studies need to be performed using a wider range of field isolates. 
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CHAPTER 6. GENERAL CONCLUSIONS 
General Discussion 
Mycoplasma hyopneumoniae is one of the most economically important pathogens of 
pigs and is found throughout the world in most pig-producing countries. It is a primary 
pathogen and the causative agent of porcine enzootic pneumonia a disease usually 
characterized by high morbidity and low mortality. Microscopic lesions consist of 
peribronchiolar and perivascular lymphoid cuffing with infiltrates of inflammatory cells in 
the airways. Mycoplasma hyopneumoniae is an important component of the porcine 
respiratory disease complex made up of bacteria such as Pasteurella multocida and 
Bordetella bronchiseptica and viruses including the porcine reproductive and respiratory 
virus (PRRSV), swine influenza virus and porcine circovirus 2 (PCV2). Mycoplasma 
hyopneumoniae not only contributes additively to this complex, but also potentiates the 
disease produced by both PRRSV and PCV2 by increasing both the severity and duration of 
disease caused by these viruses.  
Until recently, it was unknown if all isolates of M. hyopneumoniae were equivalent in 
their capacity to induce pneumonia. This is due in part to the multi-factorial nature of disease 
in pigs in the field where a number of organisms and environmental factors affect pigs 
concurrently. Therefore, assessing the relative contributions of these factors is complicated.  
In the challenge study comparing four field isolates, differences in the level of 
virulence among the isolates were observed. Because the virulence factors in M. 
hyopneumoniae are poorly understood and the protective immune response against this 
organism has not yet been defined in pigs, we attempted to determine if any marker(s) 
correlated with increased virulence. While no in vitro or in vivo growth traits or immune 
parameters measured in this study directly correlated with virulence, two M. hyopneumoniae-
specific indirect ELISAs were found to be less sensitive than a competitive-inhibition ELISA 
at 28 DPC. 
Much of the genome of M. hyopneumoniae is unique to this organism and identifying 
conserved genes for PCR assays is difficult. A large number of published PCR assays exist 
and some of these were developed before the functions of their gene-targets were known. 
Our findings showed that many of these tests produced false-negative results when DNA 
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from a collection of field isolates was assayed. Because no single currently published real-
time assay existed that could detect all isolates of M. hyopneumoniae, two new real-time 
PCR assays were developed that have detected all isolates tested to date. These assays are a 
significant improvement over previously described nested-set or real-time PCR assays and 
provide a means of quantifying M. hyopneumoniae that was not previously available. 
Three M. hyopneumoniae-specific ELISAs are currently used in the United States. 
Two are indirect ELISAs manufactured by similar techniques that primarily differ in the 
strain of M. hyopneumoniae used for antigen production. The third ELISA is a competitive-
inhibition ELISA that targets a single internal protein of M. hyopneumoniae. We found the 
competitive-inhibition ELISA to be more sensitive at earlier time-points than either of the 
indirect ELISAs in accordance with previous findings. While the two indirect ELISAs 
performed comparably over all, they differed in approximately one-quarter of the individual 
results. Further, one field isolate of M. hyopneumoniae was identified that elicited antibodies 
in pigs that were not detected as well by the indirect ELISAs. These results reinforce the 
recommendation that M. hyopneumoniae-specific ELISAs should be used on a herd-wide 
basis and not for individual pig screening. 
 Currently, no M. hyopneumoniae vaccine prevents colonization in pigs from 
occurring, although vaccines have been shown to decrease the level of pneumonia caused 
after infection. A challenge study was performed using two recent field isolates of M. 
hyopneumoniae to determine if variation in isolates affects the ability of a M. hyopneumoniae 
bacterin to protect against disease. One of these isolates induced approximately twice as 
many lung lesions as the other isolate. Accordingly, vaccinated pigs that were challenged 
with the more virulent isolate had increased levels of macroscopic pneumonia compared to 
vaccinated pigs in the other challenge group. Although for both field isolates, pigs in the 
vaccinated/challenged groups had significantly less pneumonia than did pigs in the 
corresponding unvaccinated/challenged groups demonstrating a measure of protection 
against newer field isolates.  
Together these studies provide novel in vivo and in vitro comparisons of field isolates 
of M. hyopneumoniae. They demonstrated variability at the genetic and proteomic levels that 
impact virulence, diagnosis and prevention of disease in the pig. 
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Recommendations for Future Research 
No traits were definitively correlated to specific virulence factors in high versus low 
pathogenic isolates. Because pig-to-pig variation is common in M. hyopneumoniae challenge 
studies, future studies should include increased numbers of pigs. The isolates used in all of 
our studies came from clinical cases submitted for necropsy. It may be beneficial to identify 
more isolates from herds that are subclinical in order to more easily identify distinct traits 
associated with virulence. Other technologies targeting genetic (microarray) and proteomic 
(MALDI-TOF) differences should also be employed. 
Diagnostic assays for M. hyopneumoniae are hampered by the unique genetic and 
immune characteristics associated with the organism and the disease it causes. As more 
information concerning gene function and virulence factors becomes known, improvements 
in the different assays can be made. Two new real-time assays were developed and have 
detected all isolates of M. hyopneumoniae tested in our collection. These assays should be 
further validated using isolates world-wide. This study is already underway. 
Future studies should also work to improve ELISAs for M. hyopneumoniae. A new 
ELISA should target more than one protein to guard against false-negatives and the antigen 
should be well-defined rather than a crude protein preparation to guard against false-positive 
results. A study with these aims has already been outlined in a grant submission. 
All vaccines for M. hyopneumoniae are bacterins. No modified-live or sub-unit 
vaccines exist. Future studies may be able to identify candidate proteins for sub-unit, or DNA 
vaccines. In the short-term, it may be useful to update the strains used in the killed vaccines, 
or include a mixture of strains in order to provide improved protection. Challenge studies 
should be performed using field isolates with a wide range of virulence and genetic diversity 
in order to assess protection. 
Future studies should more clearly define the immune response in pigs infected with 
M. hyopneumoniae. A microarray of immune-related genes in the pig is being employed to 
do this. Techniques such as tracheal epithelial explants, and laser-capture microdissection 
will aid in identifying the specific contributions of individual cell types to the disease process 
as well as to the immune response. 
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